drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00692 | DB10675 | 274 | 961 | [
"DDInter1448",
"DDInter1065"
] | Phentolamine | Licorice | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically. | Licorice allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
274,
24,
961
]
],
[
[
274,
24,
885
],
[
885,
24,
961
]
],
[
[
274,
63,
1061
],
[
1061,
24,
961
]
],
[
[
274,
24,
885
],
[
885,
24,
1637
],
[
1637,
24,
961
]
],
[
[
274,
63,
1061
],
[
1061,
1,
885
],
[
885,
24,
961
]
],
[
[
274,
21,
28714
],
[
28714,
60,
870
],
[
870,
24,
961
]
],
[
[
274,
24,
885
],
[
885,
40,
1061
],
[
1061,
24,
961
]
],
[
[
274,
63,
1061
],
[
1061,
24,
1637
],
[
1637,
24,
961
]
],
[
[
274,
24,
714
],
[
714,
63,
1214
],
[
1214,
24,
961
]
],
[
[
274,
63,
1061
],
[
1061,
63,
1214
],
[
1214,
24,
961
]
]
] | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} (Compound) resembles {v} (Compound)",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
]
] | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Phentolamine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Licorice |
DB00564 | DB01069 | 1,236 | 401 | [
"DDInter293",
"DDInter1533"
] | Carbamazepine | Promethazine | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
1236,
24,
401
]
],
[
[
1236,
40,
11245
],
[
11245,
1,
401
]
],
[
[
1236,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1236,
1,
1506
],
[
1506,
40,
401
]
],
[
[
1236,
1,
1405
],
[
1405,
24,
401
]
],
[
[
1236,
24,
104
],
[
104,
24,
401
]
],
[
[
1236,
6,
7603
],
[
7603,
45,
401
]
],
[
[
1236,
21,
28709
],
[
28709,
60,
401
]
],
[
[
1236,
24,
112
],
[
112,
23,
401
]
],
[
[
1236,
25,
1297
],
[
1297,
63,
401
]
]
] | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Ethopropazine"
],
[
"Ethopropazine",
"{u} (Compound) resembles {v} (Compound)",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Desipramine"
],
[
"Desipramine",
"{u} (Compound) resembles {v} (Compound)",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP2B6"
],
[
"CYP2B6",
"{u} (Gene) is bound by {v} (Compound)",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promethazine"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
]
] | Carbamazepine (Compound) resembles Ethopropazine (Compound) and Ethopropazine (Compound) resembles Promethazine (Compound)
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Carbamazepine (Compound) resembles Desipramine (Compound) and Desipramine (Compound) resembles Promethazine (Compound)
Carbamazepine (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Carbamazepine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Promethazine (Compound)
Carbamazepine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound)
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Promethazine
Carbamazepine may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Promethazine |
DB00749 | DB01050 | 59 | 848 | [
"DDInter699",
"DDInter900"
] | Etodolac | Ibuprofen | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer. | Moderate | 1 | [
[
[
59,
24,
848
]
],
[
[
59,
6,
1829
],
[
1829,
45,
848
]
],
[
[
59,
10,
11666
],
[
11666,
49,
848
]
],
[
[
59,
54,
19122
],
[
19122,
15,
848
]
],
[
[
59,
21,
28652
],
[
28652,
60,
848
]
],
[
[
59,
23,
16
],
[
16,
62,
848
]
],
[
[
59,
62,
752
],
[
752,
23,
848
]
],
[
[
59,
23,
1194
],
[
1194,
23,
848
]
],
[
[
59,
24,
1047
],
[
1047,
63,
848
]
],
[
[
59,
63,
20
],
[
20,
24,
848
]
]
] | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} (Compound) palliates {v} (Disease)",
"osteoarthritis"
],
[
"osteoarthritis",
"{u} (Disease) is palliated by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Nonsteroidal Anti-inflammatory Compounds"
],
[
"Nonsteroidal Anti-inflammatory Compounds",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} (Compound) causes {v} (Side Effect)",
"Colitis"
],
[
"Colitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
]
] | Etodolac (Compound) binds ALB (Gene) and ALB (Gene) is bound by Ibuprofen (Compound)
Etodolac (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Ibuprofen (Compound)
Etodolac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Ibuprofen (Compound)
Etodolac (Compound) causes Colitis (Side Effect) and Colitis (Side Effect) is caused by Ibuprofen (Compound)
Etodolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Ibuprofen
Etodolac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ibuprofen
Etodolac may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Ibuprofen
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen |
DB06589 | DB09034 | 1,250 | 1,313 | [
"DDInter1400",
"DDInter1733"
] | Pazopanib | Suvorexant | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
1250,
24,
1313
]
],
[
[
1250,
23,
1135
],
[
1135,
62,
1313
]
],
[
[
1250,
63,
1213
],
[
1213,
24,
1313
]
],
[
[
1250,
24,
1619
],
[
1619,
63,
1313
]
],
[
[
1250,
64,
752
],
[
752,
24,
1313
]
],
[
[
1250,
25,
982
],
[
982,
63,
1313
]
],
[
[
1250,
24,
1040
],
[
1040,
24,
1313
]
],
[
[
1250,
25,
39
],
[
39,
24,
1313
]
],
[
[
1250,
25,
760
],
[
760,
64,
1313
]
],
[
[
1250,
63,
1419
],
[
1419,
25,
1313
]
]
] | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
]
] | Pazopanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Pazopanib may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Pazopanib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Pazopanib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Pazopanib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Suvorexant
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Suvorexant |
DB00619 | DB01126 | 1,419 | 1,260 | [
"DDInter909",
"DDInter611"
] | Imatinib | Dutasteride | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediator that plays a role in the development and enlargement of the prostate gland. Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to enhance the therapeutic response. Its clinical efficacy against benign prostate hyperplasia in male patients is comparable to that of [finasteride], a specific type II 5α-reductase inhibitor. However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled trials in androgenetic alopecia.[A178333,A178336] | Moderate | 1 | [
[
[
1419,
24,
1260
]
],
[
[
1419,
6,
7524
],
[
7524,
45,
1260
]
],
[
[
1419,
21,
29532
],
[
29532,
60,
1260
]
],
[
[
1419,
25,
129
],
[
129,
63,
1260
]
],
[
[
1419,
24,
1017
],
[
1017,
63,
1260
]
],
[
[
1419,
24,
86
],
[
86,
24,
1260
]
],
[
[
1419,
35,
478
],
[
478,
63,
1260
]
],
[
[
1419,
62,
1101
],
[
1101,
24,
1260
]
],
[
[
1419,
63,
600
],
[
600,
24,
1260
]
],
[
[
1419,
6,
7524
],
[
7524,
45,
284
],
[
284,
40,
1260
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Sexual dysfunction"
],
[
"Sexual dysfunction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Finasteride"
],
[
"Finasteride",
"{u} (Compound) resembles {v} (Compound)",
"Dutasteride"
]
]
] | Imatinib (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Dutasteride (Compound)
Imatinib (Compound) causes Sexual dysfunction (Side Effect) and Sexual dysfunction (Side Effect) is caused by Dutasteride (Compound)
Imatinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dutasteride
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Dutasteride
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Dutasteride
Imatinib (Compound) resembles Nilotinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dutasteride
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Dutasteride
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dutasteride
Imatinib (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Finasteride (Compound) and Finasteride (Compound) resembles Dutasteride (Compound) |
DB01232 | DB08907 | 1,327 | 1,344 | [
"DDInter1640",
"DDInter280"
] | Saquinavir | Canagliflozin | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
1327,
24,
1344
]
],
[
[
1327,
24,
549
],
[
549,
1,
1344
]
],
[
[
1327,
6,
5912
],
[
5912,
45,
1344
]
],
[
[
1327,
21,
28962
],
[
28962,
60,
1344
]
],
[
[
1327,
24,
1033
],
[
1033,
63,
1344
]
],
[
[
1327,
64,
1486
],
[
1486,
24,
1344
]
],
[
[
1327,
63,
176
],
[
176,
24,
1344
]
],
[
[
1327,
24,
850
],
[
850,
24,
1344
]
],
[
[
1327,
1,
915
],
[
915,
24,
1344
]
],
[
[
1327,
25,
1019
],
[
1019,
63,
1344
]
]
] | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperkalaemia"
],
[
"Hyperkalaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
]
] | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Saquinavir (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Canagliflozin (Compound)
Saquinavir (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Canagliflozin (Compound)
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Saquinavir may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Saquinavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Saquinavir may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin |
DB00673 | DB09054 | 723 | 384 | [
"DDInter112",
"DDInter905"
] | Aprepitant | Idelalisib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
723,
24,
384
]
],
[
[
723,
23,
222
],
[
222,
23,
384
]
],
[
[
723,
62,
1230
],
[
1230,
23,
384
]
],
[
[
723,
23,
1627
],
[
1627,
62,
384
]
],
[
[
723,
24,
555
],
[
555,
23,
384
]
],
[
[
723,
24,
1618
],
[
1618,
24,
384
]
],
[
[
723,
63,
289
],
[
289,
24,
384
]
],
[
[
723,
62,
1101
],
[
1101,
24,
384
]
],
[
[
723,
23,
466
],
[
466,
63,
384
]
],
[
[
723,
24,
1586
],
[
1586,
63,
384
]
]
] | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cerivastatin"
],
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
],
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
]
] | Aprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib |
DB08912 | DB09381 | 1,040 | 192 | [
"DDInter462",
"DDInter678"
] | Dabrafenib | Esterified estrogens | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis. | Moderate | 1 | [
[
[
1040,
24,
192
]
],
[
[
1040,
63,
752
],
[
752,
23,
192
]
],
[
[
1040,
25,
1019
],
[
1019,
63,
192
]
],
[
[
1040,
63,
5
],
[
5,
24,
192
]
],
[
[
1040,
24,
913
],
[
913,
63,
192
]
],
[
[
1040,
24,
98
],
[
98,
24,
192
]
],
[
[
1040,
62,
1101
],
[
1101,
24,
192
]
],
[
[
1040,
63,
752
],
[
752,
24,
1264
],
[
1264,
23,
192
]
],
[
[
1040,
25,
1019
],
[
1019,
63,
5
],
[
5,
24,
192
]
],
[
[
1040,
63,
5
],
[
5,
24,
1019
],
[
1019,
63,
192
]
]
] | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
]
] | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Dabrafenib may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Dabrafenib may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens |
DB00717 | DB09036 | 1,197 | 812 | [
"DDInter1312",
"DDInter1668"
] | Norethisterone | Siltuximab | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol]. Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962. | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. | Moderate | 1 | [
[
[
1197,
24,
812
]
],
[
[
1197,
63,
1031
],
[
1031,
24,
812
]
],
[
[
1197,
1,
566
],
[
566,
24,
812
]
],
[
[
1197,
40,
1657
],
[
1657,
24,
812
]
],
[
[
1197,
24,
259
],
[
259,
24,
812
]
],
[
[
1197,
63,
1057
],
[
1057,
25,
812
]
],
[
[
1197,
24,
1510
],
[
1510,
25,
812
]
],
[
[
1197,
63,
1031
],
[
1031,
24,
371
],
[
371,
24,
812
]
],
[
[
1197,
1,
566
],
[
566,
63,
1031
],
[
1031,
24,
812
]
],
[
[
1197,
40,
1657
],
[
1657,
1,
566
],
[
566,
24,
812
]
]
] | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
],
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Desogestrel"
],
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
],
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Desogestrel"
],
[
"Desogestrel",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
],
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
]
] | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Norethisterone (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Norethisterone (Compound) resembles Desogestrel (Compound) and Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Siltuximab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Siltuximab
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Norethisterone (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Norethisterone (Compound) resembles Desogestrel (Compound) and Desogestrel (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab |
DB00795 | DB01028 | 50 | 1,332 | [
"DDInter1725",
"DDInter1179"
] | Sulfasalazine | Methoxyflurane | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness. | Moderate | 1 | [
[
[
50,
24,
1332
]
],
[
[
50,
24,
1448
],
[
1448,
63,
1332
]
],
[
[
50,
63,
1512
],
[
1512,
24,
1332
]
],
[
[
50,
40,
712
],
[
712,
63,
1332
]
],
[
[
50,
24,
361
],
[
361,
24,
1332
]
],
[
[
50,
25,
1527
],
[
1527,
64,
1332
]
],
[
[
50,
25,
629
],
[
629,
25,
1332
]
],
[
[
50,
24,
1448
],
[
1448,
63,
1512
],
[
1512,
24,
1332
]
],
[
[
50,
63,
1512
],
[
1512,
6,
7950
],
[
7950,
45,
1332
]
],
[
[
50,
24,
123
],
[
123,
63,
1448
],
[
1448,
63,
1332
]
]
] | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) resembles {v} (Compound)",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Methoxyflurane"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
]
] | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Sulfasalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Sulfasalazine may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Methoxyflurane
Sulfasalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Methoxyflurane
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Methoxyflurane (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane |
DB00620 | DB00653 | 175 | 544 | [
"DDInter1855",
"DDInter1120"
] | Triamcinolone | Magnesium sulfate | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) | Moderate | 1 | [
[
[
175,
24,
544
]
],
[
[
175,
21,
28642
],
[
28642,
60,
544
]
],
[
[
175,
24,
1579
],
[
1579,
63,
544
]
],
[
[
175,
25,
246
],
[
246,
63,
544
]
],
[
[
175,
40,
167
],
[
167,
63,
544
]
],
[
[
175,
64,
839
],
[
839,
24,
544
]
],
[
[
175,
63,
84
],
[
84,
24,
544
]
],
[
[
175,
23,
1283
],
[
1283,
63,
544
]
],
[
[
175,
24,
1081
],
[
1081,
24,
544
]
],
[
[
175,
40,
251
],
[
251,
24,
544
]
]
] | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
],
[
"Pancuronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
]
] | Triamcinolone (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Magnesium sulfate (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Triamcinolone may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Triamcinolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Triamcinolone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Triamcinolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate |
DB00980 | DB12010 | 969 | 214 | [
"DDInter1564",
"DDInter785"
] | Ramelteon | Fostamatinib | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
969,
24,
214
]
],
[
[
969,
63,
600
],
[
600,
24,
214
]
],
[
[
969,
24,
1362
],
[
1362,
24,
214
]
],
[
[
969,
24,
1017
],
[
1017,
63,
214
]
],
[
[
969,
64,
475
],
[
475,
24,
214
]
],
[
[
969,
24,
609
],
[
609,
25,
214
]
],
[
[
969,
63,
600
],
[
600,
25,
976
],
[
976,
24,
214
]
],
[
[
969,
63,
1144
],
[
1144,
63,
723
],
[
723,
24,
214
]
],
[
[
969,
24,
1362
],
[
1362,
64,
976
],
[
976,
24,
214
]
],
[
[
969,
63,
1324
],
[
1324,
24,
976
],
[
976,
24,
214
]
]
] | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
]
] | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ramelteon may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib |
DB00281 | DB01362 | 608 | 497 | [
"DDInter1066",
"DDInter960"
] | Lidocaine | Iohexol | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
608,
25,
497
]
],
[
[
608,
18,
8109
],
[
8109,
57,
497
]
],
[
[
608,
21,
28681
],
[
28681,
60,
497
]
],
[
[
608,
24,
1523
],
[
1523,
24,
497
]
],
[
[
608,
63,
88
],
[
88,
24,
497
]
],
[
[
608,
24,
1592
],
[
1592,
63,
497
]
],
[
[
608,
64,
228
],
[
228,
24,
497
]
],
[
[
608,
35,
1401
],
[
1401,
24,
497
]
],
[
[
608,
23,
998
],
[
998,
25,
497
]
],
[
[
608,
24,
1267
],
[
1267,
64,
497
]
]
] | [
[
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} (Compound) downregulates {v} (Gene)",
"NVL"
],
[
"NVL",
"{u} (Gene) is downregulated by {v} (Compound)",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
],
[
"Amifampridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
]
] | Lidocaine (Compound) downregulates NVL (Gene) and NVL (Gene) is downregulated by Iohexol (Compound)
Lidocaine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Lidocaine may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Lidocaine (Compound) resembles Procainamide (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Phenylbutazone and Phenylbutazone may lead to a major life threatening interaction when taken with Iohexol
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine and Amifampridine may lead to a major life threatening interaction when taken with Iohexol |
DB00515 | DB00564 | 589 | 1,236 | [
"DDInter387",
"DDInter293"
] | Cisplatin | Carbamazepine | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder. | Moderate | 1 | [
[
[
589,
24,
1236
]
],
[
[
589,
63,
508
],
[
508,
1,
1236
]
],
[
[
589,
6,
4973
],
[
4973,
45,
1236
]
],
[
[
589,
21,
29034
],
[
29034,
60,
1236
]
],
[
[
589,
63,
599
],
[
599,
24,
1236
]
],
[
[
589,
24,
309
],
[
309,
63,
1236
]
],
[
[
589,
24,
663
],
[
663,
24,
1236
]
],
[
[
589,
25,
908
],
[
908,
63,
1236
]
],
[
[
589,
64,
581
],
[
581,
24,
1236
]
],
[
[
589,
25,
1292
],
[
1292,
64,
1236
]
]
] | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Urinary tract disorder"
],
[
"Urinary tract disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
]
]
] | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Carbamazepine (Compound)
Cisplatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carbamazepine (Compound)
Cisplatin (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Carbamazepine (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Cisplatin may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Cisplatin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Cisplatin may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Carbamazepine |
DB01039 | DB04951 | 535 | 187 | [
"DDInter718",
"DDInter1477"
] | Fenofibrate | Pirfenidone | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF. | Moderate | 1 | [
[
[
535,
24,
187
]
],
[
[
535,
63,
663
],
[
663,
24,
187
]
],
[
[
535,
24,
850
],
[
850,
63,
187
]
],
[
[
535,
25,
1510
],
[
1510,
64,
187
]
],
[
[
535,
25,
1377
],
[
1377,
25,
187
]
],
[
[
535,
63,
663
],
[
663,
63,
168
],
[
168,
23,
187
]
],
[
[
535,
63,
912
],
[
912,
24,
168
],
[
168,
23,
187
]
],
[
[
535,
24,
850
],
[
850,
63,
168
],
[
168,
23,
187
]
],
[
[
535,
63,
300
],
[
300,
24,
1017
],
[
1017,
63,
187
]
],
[
[
535,
63,
660
],
[
660,
62,
168
],
[
168,
23,
187
]
]
] | [
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
],
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pirfenidone"
]
]
] | Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Fenofibrate may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Pirfenidone
Fenofibrate may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Pirfenidone
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Letrozole and Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone |
DB00281 | DB00794 | 608 | 759 | [
"DDInter1066",
"DDInter1521"
] | Lidocaine | Primidone | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Minor | 0 | [
[
[
608,
23,
759
]
],
[
[
608,
23,
697
],
[
697,
40,
759
]
],
[
[
608,
62,
362
],
[
362,
1,
759
]
],
[
[
608,
23,
157
],
[
157,
1,
759
]
],
[
[
608,
6,
6017
],
[
6017,
45,
759
]
],
[
[
608,
21,
28730
],
[
28730,
60,
759
]
],
[
[
608,
24,
752
],
[
752,
23,
759
]
],
[
[
608,
23,
1101
],
[
1101,
23,
759
]
],
[
[
608,
24,
908
],
[
908,
63,
759
]
],
[
[
608,
24,
723
],
[
723,
24,
759
]
]
] | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ethotoin"
],
[
"Ethotoin",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Psychotic disorder"
],
[
"Psychotic disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
]
] | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Ethotoin and Ethotoin (Compound) resembles Primidone (Compound)
Lidocaine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Primidone (Compound)
Lidocaine (Compound) causes Psychotic disorder (Side Effect) and Psychotic disorder (Side Effect) is caused by Primidone (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Primidone
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Primidone
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Primidone |
DB11691 | DB11901 | 1,499 | 913 | [
"DDInter1258",
"DDInter107"
] | Naldemedine | Apalutamide | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Major | 2 | [
[
[
1499,
25,
913
]
],
[
[
1499,
63,
600
],
[
600,
24,
913
]
],
[
[
1499,
24,
1320
],
[
1320,
63,
913
]
],
[
[
1499,
63,
1623
],
[
1623,
25,
913
]
],
[
[
1499,
24,
988
],
[
988,
64,
913
]
],
[
[
1499,
24,
960
],
[
960,
25,
913
]
],
[
[
1499,
63,
600
],
[
600,
25,
312
],
[
312,
23,
913
]
],
[
[
1499,
63,
609
],
[
609,
64,
312
],
[
312,
23,
913
]
],
[
[
1499,
24,
1320
],
[
1320,
62,
608
],
[
608,
23,
913
]
],
[
[
1499,
63,
495
],
[
495,
62,
112
],
[
112,
23,
913
]
]
] | [
[
[
"Naldemedine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
],
[
"Voxelotor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
],
[
"Istradefylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
]
] | Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may lead to a major life threatening interaction when taken with Apalutamide
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor and Voxelotor may lead to a major life threatening interaction when taken with Apalutamide
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline and Istradefylline may lead to a major life threatening interaction when taken with Apalutamide
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine and Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide |
DB08868 | DB12893 | 1,011 | 586 | [
"DDInter737",
"DDInter1629"
] | Fingolimod | Sacituzumab govitecan | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.[L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated approval for the treatment of mTNBC patients who have undergone two or more prior therapies. As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects. In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] | Major | 2 | [
[
[
1011,
25,
586
]
],
[
[
1011,
25,
270
],
[
270,
24,
586
]
],
[
[
1011,
64,
58
],
[
58,
24,
586
]
],
[
[
1011,
64,
1377
],
[
1377,
25,
586
]
],
[
[
1011,
25,
1619
],
[
1619,
25,
586
]
],
[
[
1011,
25,
270
],
[
270,
63,
58
],
[
58,
24,
586
]
],
[
[
1011,
64,
58
],
[
58,
24,
270
],
[
270,
24,
586
]
],
[
[
1011,
25,
713
],
[
713,
24,
270
],
[
270,
24,
586
]
],
[
[
1011,
64,
1377
],
[
1377,
25,
270
],
[
270,
24,
586
]
],
[
[
1011,
25,
1510
],
[
1510,
25,
270
],
[
270,
24,
586
]
]
] | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
]
] | Fingolimod may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Fingolimod may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Fingolimod may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Sacituzumab govitecan
Fingolimod may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Sacituzumab govitecan
Fingolimod may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Fingolimod may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Fingolimod may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Fingolimod may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Fingolimod may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan |
DB00026 | DB06043 | 1,184 | 1,644 | [
"DDInter94",
"DDInter1328"
] | Anakinra | Olaratumab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016. | Moderate | 1 | [
[
[
1184,
24,
1644
]
],
[
[
1184,
24,
1531
],
[
1531,
63,
1644
]
],
[
[
1184,
24,
599
],
[
599,
24,
1644
]
],
[
[
1184,
25,
1137
],
[
1137,
64,
1644
]
],
[
[
1184,
25,
1377
],
[
1377,
25,
1644
]
],
[
[
1184,
64,
1057
],
[
1057,
25,
1644
]
],
[
[
1184,
24,
1531
],
[
1531,
24,
287
],
[
287,
63,
1644
]
],
[
[
1184,
24,
287
],
[
287,
63,
1531
],
[
1531,
63,
1644
]
],
[
[
1184,
25,
1137
],
[
1137,
64,
1531
],
[
1531,
63,
1644
]
],
[
[
1184,
25,
1377
],
[
1377,
25,
1531
],
[
1531,
63,
1644
]
]
] | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaratumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaratumab"
]
]
] | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaratumab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Olaratumab
Anakinra may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Olaratumab
Anakinra may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Olaratumab
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Olaratumab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Olaratumab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaratumab
Anakinra may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaratumab
Anakinra may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaratumab |
DB00357 | DB00358 | 1,051 | 1,010 | [
"DDInter71",
"DDInter1140"
] | Aminoglutethimide | Mefloquine | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454) | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953] | Moderate | 1 | [
[
[
1051,
24,
1010
]
],
[
[
1051,
6,
10450
],
[
10450,
45,
1010
]
],
[
[
1051,
21,
28681
],
[
28681,
60,
1010
]
],
[
[
1051,
24,
392
],
[
392,
63,
1010
]
],
[
[
1051,
23,
1612
],
[
1612,
63,
1010
]
],
[
[
1051,
25,
180
],
[
180,
63,
1010
]
],
[
[
1051,
62,
608
],
[
608,
24,
1010
]
],
[
[
1051,
24,
540
],
[
540,
64,
1010
]
],
[
[
1051,
64,
576
],
[
576,
25,
1010
]
],
[
[
1051,
6,
10450
],
[
10450,
45,
888
],
[
888,
63,
1010
]
]
] | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP19A1"
],
[
"CYP19A1",
"{u} (Gene) is bound by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP19A1"
],
[
"CYP19A1",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
]
] | Aminoglutethimide (Compound) binds CYP19A1 (Gene) and CYP19A1 (Gene) is bound by Mefloquine (Compound)
Aminoglutethimide (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Mefloquine (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Aminoglutethimide may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Mefloquine
Aminoglutethimide may lead to a major life threatening interaction when taken with Methadone and Methadone may lead to a major life threatening interaction when taken with Mefloquine
Aminoglutethimide (Compound) binds CYP19A1 (Gene) and CYP19A1 (Gene) is bound by Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine |
DB00468 | DB01227 | 1,424 | 1,301 | [
"DDInter1557",
"DDInter1043"
] | Quinine | Levacetylmethadol | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862] | Major | 2 | [
[
[
1424,
25,
1301
]
],
[
[
1424,
64,
494
],
[
494,
1,
1301
]
],
[
[
1424,
23,
307
],
[
307,
1,
1301
]
],
[
[
1424,
24,
675
],
[
675,
1,
1301
]
],
[
[
1424,
6,
8374
],
[
8374,
45,
1301
]
],
[
[
1424,
23,
112
],
[
112,
23,
1301
]
],
[
[
1424,
24,
629
],
[
629,
24,
1301
]
],
[
[
1424,
24,
144
],
[
144,
63,
1301
]
],
[
[
1424,
24,
1040
],
[
1040,
64,
1301
]
],
[
[
1424,
25,
982
],
[
982,
64,
1301
]
]
] | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
]
] | Quinine may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Levacetylmethadol (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Quinine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levacetylmethadol (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Levacetylmethadol
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Levacetylmethadol
Quinine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Levacetylmethadol |
DB05273 | DB09331 | 507 | 745 | [
"DDInter1638",
"DDInter478"
] | Samarium (153Sm) lexidronam | Daratumumab | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296] | Major | 2 | [
[
[
507,
25,
745
]
],
[
[
507,
64,
4
],
[
4,
24,
745
]
],
[
[
507,
63,
563
],
[
563,
24,
745
]
],
[
[
507,
25,
1362
],
[
1362,
24,
745
]
],
[
[
507,
24,
270
],
[
270,
63,
745
]
],
[
[
507,
25,
738
],
[
738,
63,
745
]
],
[
[
507,
64,
1064
],
[
1064,
25,
745
]
],
[
[
507,
25,
1259
],
[
1259,
64,
745
]
],
[
[
507,
25,
976
],
[
976,
25,
745
]
],
[
[
507,
64,
4
],
[
4,
63,
139
],
[
139,
24,
745
]
]
] | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
]
] | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Daratumumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Daratumumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Daratumumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab |
DB00549 | DB01018 | 522 | 1,364 | [
"DDInter1955",
"DDInter847"
] | Zafirlukast | Guanfacine | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986. | Moderate | 1 | [
[
[
522,
24,
1364
]
],
[
[
522,
6,
10215
],
[
10215,
45,
1364
]
],
[
[
522,
21,
28757
],
[
28757,
60,
1364
]
],
[
[
522,
24,
1476
],
[
1476,
63,
1364
]
],
[
[
522,
24,
372
],
[
372,
24,
1364
]
],
[
[
522,
24,
1593
],
[
1593,
64,
1364
]
],
[
[
522,
24,
1419
],
[
1419,
25,
1364
]
],
[
[
522,
63,
597
],
[
597,
25,
1364
]
],
[
[
522,
6,
10215
],
[
10215,
45,
1512
],
[
1512,
1,
1364
]
],
[
[
522,
21,
28757
],
[
28757,
60,
1512
],
[
1512,
1,
1364
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Diclofenac"
],
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound)",
"Guanfacine"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Diclofenac"
],
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound)",
"Guanfacine"
]
]
] | Zafirlukast (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Guanfacine (Compound)
Zafirlukast (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Guanfacine (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Guanfacine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Guanfacine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Guanfacine
Zafirlukast (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Diclofenac (Compound) and Diclofenac (Compound) resembles Guanfacine (Compound)
Zafirlukast (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Diclofenac (Compound) and Diclofenac (Compound) resembles Guanfacine (Compound) |
DB01377 | DB09263 | 1,283 | 1,436 | [
"DDInter1119",
"DDInter1399"
] | Magnesium oxide | Patiromer | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads. | Major | 2 | [
[
[
1283,
25,
1436
]
],
[
[
1283,
62,
1220
],
[
1220,
24,
1436
]
],
[
[
1283,
24,
853
],
[
853,
63,
1436
]
],
[
[
1283,
63,
1152
],
[
1152,
24,
1436
]
],
[
[
1283,
24,
1596
],
[
1596,
24,
1436
]
],
[
[
1283,
24,
286
],
[
286,
25,
1436
]
],
[
[
1283,
24,
460
],
[
460,
64,
1436
]
],
[
[
1283,
62,
1220
],
[
1220,
40,
870
],
[
870,
24,
1436
]
],
[
[
1283,
62,
870
],
[
870,
1,
1220
],
[
1220,
24,
1436
]
],
[
[
1283,
24,
853
],
[
853,
24,
1473
],
[
1473,
63,
1436
]
]
] | [
[
[
"Magnesium oxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
],
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
],
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
],
[
"Magnesium gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
]
] | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Patiromer
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may lead to a major life threatening interaction when taken with Patiromer
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer |
DB00604 | DB00818 | 1,425 | 898 | [
"DDInter385",
"DDInter1538"
] | Cisapride | Propofol | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries. | Moderate | 1 | [
[
[
1425,
24,
898
]
],
[
[
1425,
6,
7603
],
[
7603,
45,
898
]
],
[
[
1425,
23,
112
],
[
112,
62,
898
]
],
[
[
1425,
25,
392
],
[
392,
63,
898
]
],
[
[
1425,
24,
720
],
[
720,
63,
898
]
],
[
[
1425,
63,
355
],
[
355,
24,
898
]
],
[
[
1425,
25,
1166
],
[
1166,
24,
898
]
],
[
[
1425,
62,
475
],
[
475,
24,
898
]
],
[
[
1425,
64,
1494
],
[
1494,
24,
898
]
],
[
[
1425,
6,
7603
],
[
7603,
45,
256
],
[
256,
62,
898
]
]
] | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP2B6"
],
[
"CYP2B6",
"{u} (Gene) is bound by {v} (Compound)",
"Propofol"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propofol"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
],
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP2B6"
],
[
"CYP2B6",
"{u} (Gene) is bound by {v} (Compound)",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propofol"
]
]
] | Cisapride (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Propofol (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Propofol
Cisapride may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Cisapride may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Cisapride may cause a minor interaction that can limit clinical effects when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Cisapride may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Cisapride (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Prasugrel (Compound) and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Propofol |
DB00250 | DB08826 | 10 | 1,292 | [
"DDInter475",
"DDInter489"
] | Dapsone | Deferiprone | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. | Major | 2 | [
[
[
10,
25,
1292
]
],
[
[
10,
21,
28762
],
[
28762,
60,
1292
]
],
[
[
10,
24,
1017
],
[
1017,
63,
1292
]
],
[
[
10,
24,
45
],
[
45,
24,
1292
]
],
[
[
10,
24,
1619
],
[
1619,
64,
1292
]
],
[
[
10,
24,
1419
],
[
1419,
25,
1292
]
],
[
[
10,
64,
1064
],
[
1064,
25,
1292
]
],
[
[
10,
63,
491
],
[
491,
25,
1292
]
],
[
[
10,
25,
695
],
[
695,
25,
1292
]
],
[
[
10,
21,
28762
],
[
28762,
60,
45
],
[
45,
24,
1292
]
]
] | [
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
],
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Didanosine"
],
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
]
] | Dapsone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Deferiprone (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Deferiprone
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Deferiprone
Dapsone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Deferiprone
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Deferiprone
Dapsone may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Deferiprone
Dapsone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone |
DB00314 | DB00781 | 894 | 1,481 | [
"DDInter288",
"DDInter1489"
] | Capreomycin | Polymyxin B | Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label]. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line. | Moderate | 1 | [
[
[
894,
24,
1481
]
],
[
[
894,
24,
1441
],
[
1441,
40,
1481
]
],
[
[
894,
21,
28719
],
[
28719,
60,
1481
]
],
[
[
894,
24,
91
],
[
91,
24,
1481
]
],
[
[
894,
24,
50
],
[
50,
63,
1481
]
],
[
[
894,
25,
1132
],
[
1132,
64,
1481
]
],
[
[
894,
24,
1441
],
[
1441,
40,
966
],
[
966,
40,
1481
]
],
[
[
894,
21,
28719
],
[
28719,
60,
966
],
[
966,
40,
1481
]
],
[
[
894,
24,
91
],
[
91,
24,
1441
],
[
1441,
40,
1481
]
],
[
[
894,
24,
50
],
[
50,
63,
1441
],
[
1441,
40,
1481
]
]
] | [
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} (Compound) resembles {v} (Compound)",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} (Compound) resembles {v} (Compound)",
"Octreotide"
],
[
"Octreotide",
"{u} (Compound) resembles {v} (Compound)",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Octreotide"
],
[
"Octreotide",
"{u} (Compound) resembles {v} (Compound)",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} (Compound) resembles {v} (Compound)",
"Polymyxin B"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} (Compound) resembles {v} (Compound)",
"Polymyxin B"
]
]
] | Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Polymyxin B (Compound)
Capreomycin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Polymyxin B (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B
Capreomycin may lead to a major life threatening interaction when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Polymyxin B
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Octreotide (Compound) and Octreotide (Compound) resembles Polymyxin B (Compound)
Capreomycin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Octreotide (Compound) and Octreotide (Compound) resembles Polymyxin B (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Polymyxin B (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Polymyxin B (Compound) |
DB00390 | DB00620 | 1,252 | 175 | [
"DDInter554",
"DDInter1855"
] | Digoxin | Triamcinolone | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis. | Moderate | 1 | [
[
[
1252,
24,
175
]
],
[
[
1252,
24,
1573
],
[
1573,
1,
175
]
],
[
[
1252,
7,
7720
],
[
7720,
45,
175
]
],
[
[
1252,
6,
8374
],
[
8374,
45,
175
]
],
[
[
1252,
7,
2969
],
[
2969,
46,
175
]
],
[
[
1252,
18,
7847
],
[
7847,
46,
175
]
],
[
[
1252,
7,
1720
],
[
1720,
57,
175
]
],
[
[
1252,
18,
7359
],
[
7359,
57,
175
]
],
[
[
1252,
21,
28762
],
[
28762,
60,
175
]
],
[
[
1252,
23,
115
],
[
115,
62,
175
]
]
] | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"CDKN1A"
],
[
"CDKN1A",
"{u} (Gene) is upregulated by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"BAG3"
],
[
"BAG3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"RELB"
],
[
"RELB",
"{u} (Gene) is downregulated by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
]
]
] | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Digoxin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Triamcinolone (Compound)
Digoxin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Triamcinolone (Compound)
Digoxin (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Triamcinolone (Compound)
Digoxin (Compound) downregulates BAG3 (Gene) and BAG3 (Gene) is upregulated by Triamcinolone (Compound)
Digoxin (Compound) upregulates RELB (Gene) and RELB (Gene) is downregulated by Triamcinolone (Compound)
Digoxin (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Triamcinolone (Compound)
Digoxin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Triamcinolone (Compound)
Digoxin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Triamcinolone |
DB00762 | DB14723 | 613 | 159 | [
"DDInter973",
"DDInter1026"
] | Irinotecan | Larotrectinib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde). | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
613,
24,
159
]
],
[
[
613,
24,
466
],
[
466,
23,
159
]
],
[
[
613,
62,
1230
],
[
1230,
23,
159
]
],
[
[
613,
24,
1375
],
[
1375,
24,
159
]
],
[
[
613,
63,
307
],
[
307,
24,
159
]
],
[
[
613,
24,
1654
],
[
1654,
63,
159
]
],
[
[
613,
25,
676
],
[
676,
63,
159
]
],
[
[
613,
25,
976
],
[
976,
24,
159
]
],
[
[
613,
25,
1327
],
[
1327,
25,
159
]
],
[
[
613,
64,
1622
],
[
1622,
25,
159
]
]
] | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
]
] | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Irinotecan may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Irinotecan may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Irinotecan may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Larotrectinib
Irinotecan may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may lead to a major life threatening interaction when taken with Larotrectinib |
DB00072 | DB00099 | 550 | 440 | [
"DDInter1846",
"DDInter735"
] | Trastuzumab | Filgrastim | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells. Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly. In December 2017, FDA approved OGIVRI ( | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the peripheral blood for collection by leukapheresis in patients undergoing peripheral blood progenitor cell collection and therapy. Filgrastim was approved in the US in 1991 and there are biosimilars available with similar therapeutic indications. Tbo-filgrastim was approved by the FDA on August 29, 2012. Filgrastim-sndz was approved on March 6, 2015 and filgrastim-ayow was approved on March 2, 2022. A long-acting, pegylated G-CSF, [pegfilgrastim], was made available to increase the duration of action of the drug. | Moderate | 1 | [
[
[
550,
24,
440
]
],
[
[
550,
24,
869
],
[
869,
63,
440
]
],
[
[
550,
25,
77
],
[
77,
63,
440
]
],
[
[
550,
24,
599
],
[
599,
24,
440
]
],
[
[
550,
25,
1064
],
[
1064,
64,
440
]
],
[
[
550,
24,
869
],
[
869,
24,
37
],
[
37,
63,
440
]
],
[
[
550,
24,
738
],
[
738,
63,
37
],
[
37,
63,
440
]
],
[
[
550,
25,
77
],
[
77,
24,
37
],
[
37,
63,
440
]
],
[
[
550,
25,
770
],
[
770,
25,
37
],
[
37,
63,
440
]
],
[
[
550,
25,
77
],
[
77,
63,
552
],
[
552,
63,
440
]
]
] | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
]
] | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Trastuzumab may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Trastuzumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Filgrastim
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Trastuzumab may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Trastuzumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Trastuzumab may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim |
DB00486 | DB01203 | 1,614 | 699 | [
"DDInter1253",
"DDInter1255"
] | Nabilone | Nadolol | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979. | Moderate | 1 | [
[
[
1614,
24,
699
]
],
[
[
1614,
24,
729
],
[
729,
1,
699
]
],
[
[
1614,
21,
28882
],
[
28882,
60,
699
]
],
[
[
1614,
24,
820
],
[
820,
63,
699
]
],
[
[
1614,
24,
1264
],
[
1264,
24,
699
]
],
[
[
1614,
63,
475
],
[
475,
24,
699
]
],
[
[
1614,
40,
530
],
[
530,
24,
699
]
],
[
[
1614,
24,
729
],
[
729,
1,
493
],
[
493,
1,
699
]
],
[
[
1614,
21,
28882
],
[
28882,
60,
729
],
[
729,
1,
699
]
],
[
[
1614,
21,
28970
],
[
28970,
60,
1442
],
[
1442,
24,
699
]
]
] | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Carteolol"
],
[
"Carteolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Dry eye"
],
[
"Dry eye",
"{u} (Side Effect) is caused by {v} (Compound)",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
]
] | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Nabilone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Nadolol (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Carteolol (Compound) and Carteolol (Compound) resembles Nadolol (Compound)
Nabilone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Penbutolol (Compound) and Penbutolol (Compound) resembles Nadolol (Compound)
Nabilone (Compound) causes Dry eye (Side Effect) and Dry eye (Side Effect) is caused by Scopolamine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol |
DB11828 | DB11967 | 1,406 | 710 | [
"DDInter1281",
"DDInter210"
] | Neratinib | Binimetinib | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
1406,
24,
710
]
],
[
[
1406,
64,
441
],
[
441,
24,
710
]
],
[
[
1406,
25,
68
],
[
68,
63,
710
]
],
[
[
1406,
24,
1619
],
[
1619,
63,
710
]
],
[
[
1406,
63,
26
],
[
26,
24,
710
]
],
[
[
1406,
63,
1510
],
[
1510,
25,
710
]
],
[
[
1406,
64,
441
],
[
441,
25,
1593
],
[
1593,
24,
710
]
],
[
[
1406,
64,
1593
],
[
1593,
64,
441
],
[
441,
24,
710
]
],
[
[
1406,
25,
68
],
[
68,
64,
1593
],
[
1593,
24,
710
]
],
[
[
1406,
24,
1619
],
[
1619,
63,
441
],
[
441,
24,
710
]
]
] | [
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
]
] | Neratinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib |
DB04865 | DB06788 | 4 | 1,616 | [
"DDInter1335",
"DDInter864"
] | Omacetaxine mepesuccinate | Histrelin | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007). | Moderate | 1 | [
[
[
4,
24,
1616
]
],
[
[
4,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
4,
63,
170
],
[
170,
24,
1616
]
],
[
[
4,
25,
927
],
[
927,
63,
1616
]
],
[
[
4,
24,
52
],
[
52,
63,
1616
]
],
[
[
4,
64,
477
],
[
477,
24,
1616
]
],
[
[
4,
63,
1401
],
[
1401,
25,
1616
]
],
[
[
4,
24,
985
],
[
985,
64,
1616
]
],
[
[
4,
64,
702
],
[
702,
25,
1616
]
],
[
[
4,
25,
1618
],
[
1618,
64,
1616
]
]
] | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
]
] | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide may lead to a major life threatening interaction when taken with Histrelin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Histrelin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Histrelin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Histrelin |
DB01156 | DB01367 | 593 | 1,163 | [
"DDInter252",
"DDInter1572"
] | Bupropion | Rasagiline | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Major | 2 | [
[
[
593,
25,
1163
]
],
[
[
593,
6,
7950
],
[
7950,
45,
1163
]
],
[
[
593,
21,
28714
],
[
28714,
60,
1163
]
],
[
[
593,
64,
401
],
[
401,
24,
1163
]
],
[
[
593,
63,
1214
],
[
1214,
24,
1163
]
],
[
[
593,
25,
22
],
[
22,
24,
1163
]
],
[
[
593,
25,
1510
],
[
1510,
63,
1163
]
],
[
[
593,
24,
1362
],
[
1362,
63,
1163
]
],
[
[
593,
62,
752
],
[
752,
24,
1163
]
],
[
[
593,
25,
1039
],
[
1039,
25,
1163
]
]
] | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rasagiline"
]
]
] | Bupropion (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Rasagiline (Compound)
Bupropion (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Rasagiline (Compound)
Bupropion may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Bupropion may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Bupropion may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Bupropion may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Bupropion may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Rasagiline |
DB00738 | DB06699 | 485 | 774 | [
"DDInter1420",
"DDInter493"
] | Pentamidine | Degarelix | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Moderate | 1 | [
[
[
485,
24,
774
]
],
[
[
485,
63,
521
],
[
521,
1,
774
]
],
[
[
485,
21,
29232
],
[
29232,
60,
774
]
],
[
[
485,
23,
112
],
[
112,
23,
774
]
],
[
[
485,
63,
888
],
[
888,
24,
774
]
],
[
[
485,
24,
956
],
[
956,
24,
774
]
],
[
[
485,
24,
484
],
[
484,
63,
774
]
],
[
[
485,
64,
789
],
[
789,
24,
774
]
],
[
[
485,
25,
1487
],
[
1487,
24,
774
]
],
[
[
485,
25,
33
],
[
33,
25,
774
]
]
] | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
]
] | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Pentamidine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Degarelix
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Pentamidine may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Pentamidine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Pentamidine may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Degarelix |
DB10429 | DB11760 | 200 | 119 | [
"DDInter282",
"DDInter1742"
] | Candida albicans | Talazoparib | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306] | Moderate | 1 | [
[
[
200,
24,
119
]
],
[
[
200,
63,
599
],
[
599,
24,
119
]
],
[
[
200,
24,
351
],
[
351,
24,
119
]
],
[
[
200,
24,
1619
],
[
1619,
63,
119
]
],
[
[
200,
63,
1011
],
[
1011,
25,
119
]
],
[
[
200,
24,
676
],
[
676,
64,
119
]
],
[
[
200,
63,
599
],
[
599,
24,
66
],
[
66,
24,
119
]
],
[
[
200,
63,
713
],
[
713,
63,
66
],
[
66,
24,
119
]
],
[
[
200,
24,
351
],
[
351,
63,
66
],
[
66,
24,
119
]
],
[
[
200,
24,
1456
],
[
1456,
64,
1449
],
[
1449,
24,
119
]
]
] | [
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simeprevir"
],
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
]
] | Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Talazoparib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Talazoparib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Simeprevir and Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib |
DB00395 | DB01142 | 210 | 1,264 | [
"DDInter301",
"DDInter593"
] | Carisoprodol | Doxepin | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069]. In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential for abuse in addition to a low risk of dependence. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Moderate | 1 | [
[
[
210,
24,
1264
]
],
[
[
210,
24,
401
],
[
401,
24,
1264
]
],
[
[
210,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
210,
24,
649
],
[
649,
63,
1264
]
],
[
[
210,
6,
10215
],
[
10215,
45,
1264
]
],
[
[
210,
21,
28852
],
[
28852,
60,
1264
]
],
[
[
210,
64,
475
],
[
475,
24,
1264
]
],
[
[
210,
24,
222
],
[
222,
25,
1264
]
],
[
[
210,
24,
1376
],
[
1376,
35,
1264
]
],
[
[
210,
24,
820
],
[
820,
74,
1264
]
]
] | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
]
] | Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Carisoprodol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Doxepin (Compound)
Carisoprodol (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Doxepin (Compound)
Carisoprodol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Doxepin
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Doxepin (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin |
DB00270 | DB00619 | 1,428 | 1,419 | [
"DDInter993",
"DDInter909"
] | Isradipine | Imatinib | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Moderate | 1 | [
[
[
1428,
24,
1419
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
1419
]
],
[
[
1428,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
1428,
24,
1101
],
[
1101,
23,
1419
]
],
[
[
1428,
24,
283
],
[
283,
63,
1419
]
],
[
[
1428,
1,
84
],
[
84,
24,
1419
]
],
[
[
1428,
24,
475
],
[
475,
24,
1419
]
],
[
[
1428,
63,
1648
],
[
1648,
24,
1419
]
],
[
[
1428,
40,
854
],
[
854,
24,
1419
]
],
[
[
1428,
1,
409
],
[
409,
63,
1419
]
]
] | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nimodipine"
],
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
]
] | Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Imatinib (Compound)
Isradipine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Isradipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Isradipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Isradipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib |
DB01155 | DB01611 | 872 | 1,487 | [
"DDInter813",
"DDInter893"
] | Gemifloxacin | Hydroxychloroquine | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19. | Major | 2 | [
[
[
872,
25,
1487
]
],
[
[
872,
63,
1520
],
[
1520,
25,
1487
]
],
[
[
872,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
872,
63,
663
],
[
663,
23,
1487
]
],
[
[
872,
64,
245
],
[
245,
24,
1487
]
],
[
[
872,
24,
1283
],
[
1283,
24,
1487
]
],
[
[
872,
24,
286
],
[
286,
63,
1487
]
],
[
[
872,
63,
521
],
[
521,
24,
1487
]
],
[
[
872,
62,
147
],
[
147,
24,
1487
]
],
[
[
872,
25,
1296
],
[
1296,
63,
1487
]
]
] | [
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
]
] | Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Gemifloxacin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine
Gemifloxacin may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Gemifloxacin may lead to a major life threatening interaction when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine |
DB00443 | DB00545 | 251 | 751 | [
"DDInter195",
"DDInter1548"
] | Betamethasone | Pyridostigmine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the early use of [physostigmine] and [neostigmine]. By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.[A231004, L32408, L32413] Pyridostigmine is the current drug of choice, with superior pharmacokinetics and reduced side effects compared to [neostigmine].[L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks, relieve symptoms in congenital myasthenic syndromes, and protect against certain nerve agents, notably during the Gulf War.[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. Possible dose forms have been expanded to include extended-release tablets, syrups, and injections, marketed under various brand and generic names.[L32408, L32413] | Moderate | 1 | [
[
[
251,
24,
751
]
],
[
[
251,
24,
1372
],
[
1372,
1,
751
]
],
[
[
251,
6,
8374
],
[
8374,
45,
751
]
],
[
[
251,
21,
28751
],
[
28751,
60,
751
]
],
[
[
251,
25,
1011
],
[
1011,
63,
751
]
],
[
[
251,
1,
617
],
[
617,
63,
751
]
],
[
[
251,
24,
61
],
[
61,
63,
751
]
],
[
[
251,
40,
167
],
[
167,
63,
751
]
],
[
[
251,
24,
1372
],
[
1372,
1,
189
],
[
189,
1,
751
]
],
[
[
251,
6,
8374
],
[
8374,
45,
189
],
[
189,
1,
751
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
],
[
"Neostigmine",
"{u} (Compound) resembles {v} (Compound)",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
],
[
"Neostigmine",
"{u} (Compound) resembles {v} (Compound)",
"Rivastigmine"
],
[
"Rivastigmine",
"{u} (Compound) resembles {v} (Compound)",
"Pyridostigmine"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rivastigmine"
],
[
"Rivastigmine",
"{u} (Compound) resembles {v} (Compound)",
"Pyridostigmine"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine and Neostigmine (Compound) resembles Pyridostigmine (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pyridostigmine (Compound)
Betamethasone (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Pyridostigmine (Compound)
Betamethasone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine
Betamethasone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine and Neostigmine (Compound) resembles Rivastigmine (Compound) and Rivastigmine (Compound) resembles Pyridostigmine (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivastigmine (Compound) and Rivastigmine (Compound) resembles Pyridostigmine (Compound) |
DB00543 | DB08875 | 87 | 1,618 | [
"DDInter82",
"DDInter262"
] | Amoxapine | Cabozantinib | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Major | 2 | [
[
[
87,
25,
1618
]
],
[
[
87,
23,
112
],
[
112,
23,
1618
]
],
[
[
87,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
87,
24,
480
],
[
480,
24,
1618
]
],
[
[
87,
40,
867
],
[
867,
24,
1618
]
],
[
[
87,
25,
222
],
[
222,
24,
1618
]
],
[
[
87,
63,
322
],
[
322,
25,
1618
]
],
[
[
87,
24,
888
],
[
888,
25,
1618
]
],
[
[
87,
64,
11
],
[
11,
25,
1618
]
],
[
[
87,
25,
985
],
[
985,
64,
1618
]
]
] | [
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
]
] | Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Amoxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Amoxapine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Cabozantinib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Cabozantinib
Amoxapine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Cabozantinib
Amoxapine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Cabozantinib |
DB00006 | DB00328 | 942 | 831 | [
"DDInter217",
"DDInter921"
] | Bivalirudin | Indomethacin | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure. | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-acetic acid. The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via the arachidonic acid (AA) pathway. Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, along with other acetic acid derivatives such as [diclofenac] and [sulindac] that were also developed during the 1960s. Since then, indometacin has been extensively studied in clinical trials as one of the most potent NSAIDs in blocking prostaglandin synthesis and was among the first NSAIDs to be used in the symptomatic treatment of migraine and for headaches that eventually became known as “indomethacin-responsive” headache disorders. Most commonly used in rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute shoulder pains, and acute gouty arthritis, indometacin is currently available as oral capsules as well as other methods of administration, including rectal and intravenous formulations. Intravenous indometacin is administered to close a hemodynamically significant patent ductus arteriosus, as indicated by clinical evidence, in premature infants. Ophthalmic indometacin has been studied and used in the symptomatic treatment of postoperative ocular inflammation and pain and/or complications after cataract surgery. Although deemed effective in reducing ocular inflammation in clinical studies, topical NSAIDs were also associated with a potential reduction in corneal sensitivity accompanied by an increased risk of superficial punctate keratitis and subjective symptoms of discomfort, including pain, burning or pricking, or a tingling sensation after instillation into the cul‐de‐sac. | Moderate | 1 | [
[
[
942,
24,
831
]
],
[
[
942,
24,
1263
],
[
1263,
1,
831
]
],
[
[
942,
24,
848
],
[
848,
63,
831
]
],
[
[
942,
25,
20
],
[
20,
24,
831
]
],
[
[
942,
25,
1047
],
[
1047,
63,
831
]
],
[
[
942,
24,
1432
],
[
1432,
24,
831
]
],
[
[
942,
64,
1578
],
[
1578,
24,
831
]
],
[
[
942,
25,
4
],
[
4,
64,
831
]
],
[
[
942,
25,
1172
],
[
1172,
25,
831
]
],
[
[
942,
24,
1263
],
[
1263,
1,
24
],
[
24,
1,
831
]
]
] | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
],
[
"Bromfenac",
"{u} (Compound) resembles {v} (Compound)",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Indomethacin"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
],
[
"Bromfenac",
"{u} (Compound) resembles {v} (Compound)",
"Tolmetin"
],
[
"Tolmetin",
"{u} (Compound) resembles {v} (Compound)",
"Indomethacin"
]
]
] | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac (Compound) resembles Indomethacin (Compound)
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Bivalirudin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Bivalirudin may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Abciximab and Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin
Bivalirudin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Indomethacin
Bivalirudin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Indomethacin
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac (Compound) resembles Tolmetin (Compound) and Tolmetin (Compound) resembles Indomethacin (Compound) |
DB00477 | DB11986 | 216 | 484 | [
"DDInter363",
"DDInter648"
] | Chlorpromazine | Entrectinib | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
216,
24,
484
]
],
[
[
216,
23,
112
],
[
112,
23,
484
]
],
[
[
216,
24,
222
],
[
222,
23,
484
]
],
[
[
216,
24,
774
],
[
774,
24,
484
]
],
[
[
216,
63,
322
],
[
322,
24,
484
]
],
[
[
216,
40,
1164
],
[
1164,
24,
484
]
],
[
[
216,
23,
752
],
[
752,
24,
484
]
],
[
[
216,
35,
820
],
[
820,
24,
484
]
],
[
[
216,
24,
1619
],
[
1619,
63,
484
]
],
[
[
216,
1,
1237
],
[
1237,
24,
484
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
]
] | Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Chlorpromazine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Chlorpromazine (Compound) resembles Alimemazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Chlorpromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib |
DB00443 | DB01023 | 251 | 409 | [
"DDInter195",
"DDInter716"
] | Betamethasone | Felodipine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension. | Moderate | 1 | [
[
[
251,
24,
409
]
],
[
[
251,
63,
376
],
[
376,
40,
409
]
],
[
[
251,
24,
1081
],
[
1081,
40,
409
]
],
[
[
251,
63,
1428
],
[
1428,
1,
409
]
],
[
[
251,
6,
3996
],
[
3996,
45,
409
]
],
[
[
251,
18,
5901
],
[
5901,
57,
409
]
],
[
[
251,
21,
28722
],
[
28722,
60,
409
]
],
[
[
251,
63,
1031
],
[
1031,
23,
409
]
],
[
[
251,
24,
1479
],
[
1479,
24,
409
]
],
[
[
251,
24,
1017
],
[
1017,
63,
409
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"NR3C2"
],
[
"NR3C2",
"{u} (Gene) is bound by {v} (Compound)",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} (Compound) downregulates {v} (Gene)",
"GJA1"
],
[
"GJA1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Felodipine (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Felodipine (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Felodipine (Compound)
Betamethasone (Compound) binds NR3C2 (Gene) and NR3C2 (Gene) is bound by Felodipine (Compound)
Betamethasone (Compound) downregulates GJA1 (Gene) and GJA1 (Gene) is downregulated by Felodipine (Compound)
Betamethasone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Felodipine (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Felodipine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Felodipine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Felodipine |
DB00278 | DB00939 | 291 | 1,338 | [
"DDInter117",
"DDInter1135"
] | Argatroban | Meclofenamic acid | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban. | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
291,
24,
1338
]
],
[
[
291,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
291,
21,
28900
],
[
28900,
60,
1338
]
],
[
[
291,
25,
1347
],
[
1347,
24,
1338
]
],
[
[
291,
64,
1271
],
[
1271,
24,
1338
]
],
[
[
291,
25,
1564
],
[
1564,
63,
1338
]
],
[
[
291,
63,
599
],
[
599,
24,
1338
]
],
[
[
291,
24,
121
],
[
121,
24,
1338
]
],
[
[
291,
64,
1172
],
[
1172,
25,
1338
]
],
[
[
291,
25,
500
],
[
500,
64,
1338
]
]
] | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alteplase"
],
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meclofenamic acid"
]
]
] | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Argatroban (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Meclofenamic acid (Compound)
Argatroban may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Argatroban may lead to a major life threatening interaction when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Argatroban may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Argatroban may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Meclofenamic acid
Argatroban may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Meclofenamic acid |
DB00563 | DB00982 | 663 | 1,517 | [
"DDInter1174",
"DDInter991"
] | Methotrexate | Isotretinoin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-containing product was FDA approved on 7 May 1982. | Moderate | 1 | [
[
[
663,
24,
1517
]
],
[
[
663,
64,
640
],
[
640,
25,
1517
]
],
[
[
663,
7,
18134
],
[
18134,
46,
1517
]
],
[
[
663,
18,
6602
],
[
6602,
46,
1517
]
],
[
[
663,
18,
15501
],
[
15501,
57,
1517
]
],
[
[
663,
7,
2389
],
[
2389,
57,
1517
]
],
[
[
663,
6,
8569
],
[
8569,
57,
1517
]
],
[
[
663,
21,
28897
],
[
28897,
60,
1517
]
],
[
[
663,
63,
362
],
[
362,
24,
1517
]
],
[
[
663,
24,
868
],
[
868,
63,
1517
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"POLD4"
],
[
"POLD4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"LBR"
],
[
"LBR",
"{u} (Gene) is upregulated by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"CCDC85B"
],
[
"CCDC85B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"TYMS"
],
[
"TYMS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Coma"
],
[
"Coma",
"{u} (Side Effect) is caused by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
]
] | Methotrexate may lead to a major life threatening interaction when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Isotretinoin
Methotrexate (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Isotretinoin (Compound)
Methotrexate (Compound) downregulates LBR (Gene) and LBR (Gene) is upregulated by Isotretinoin (Compound)
Methotrexate (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Isotretinoin (Compound)
Methotrexate (Compound) upregulates CCDC85B (Gene) and CCDC85B (Gene) is downregulated by Isotretinoin (Compound)
Methotrexate (Compound) binds TYMS (Gene) and TYMS (Gene) is downregulated by Isotretinoin (Compound)
Methotrexate (Compound) causes Coma (Side Effect) and Coma (Side Effect) is caused by Isotretinoin (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin |
DB01254 | DB01263 | 1,213 | 859 | [
"DDInter484",
"DDInter1494"
] | Dasatinib | Posaconazole | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Major | 2 | [
[
[
1213,
25,
859
]
],
[
[
1213,
6,
4973
],
[
4973,
45,
859
]
],
[
[
1213,
21,
29852
],
[
29852,
60,
859
]
],
[
[
1213,
62,
112
],
[
112,
23,
859
]
],
[
[
1213,
63,
1101
],
[
1101,
23,
859
]
],
[
[
1213,
24,
286
],
[
286,
63,
859
]
],
[
[
1213,
63,
618
],
[
618,
24,
859
]
],
[
[
1213,
25,
384
],
[
384,
63,
859
]
],
[
[
1213,
64,
1127
],
[
1127,
24,
859
]
],
[
[
1213,
25,
39
],
[
39,
64,
859
]
]
] | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Hypoalbuminaemia"
],
[
"Hypoalbuminaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nizatidine"
],
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
]
] | Dasatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Dasatinib (Compound) causes Hypoalbuminaemia (Side Effect) and Hypoalbuminaemia (Side Effect) is caused by Posaconazole (Compound)
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Posaconazole
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Posaconazole
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Dasatinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Dasatinib may lead to a major life threatening interaction when taken with Nizatidine and Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Dasatinib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Posaconazole |
DB00880 | DB01067 | 359 | 959 | [
"DDInter360",
"DDInter826"
] | Chlorothiazide | Glipizide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. | Moderate | 1 | [
[
[
359,
24,
959
]
],
[
[
359,
63,
245
],
[
245,
40,
959
]
],
[
[
359,
24,
1411
],
[
1411,
1,
959
]
],
[
[
359,
21,
28746
],
[
28746,
60,
959
]
],
[
[
359,
63,
660
],
[
660,
23,
959
]
],
[
[
359,
24,
1220
],
[
1220,
63,
959
]
],
[
[
359,
63,
1674
],
[
1674,
24,
959
]
],
[
[
359,
62,
126
],
[
126,
24,
959
]
],
[
[
359,
24,
848
],
[
848,
24,
959
]
],
[
[
359,
40,
178
],
[
178,
63,
959
]
]
] | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
]
] | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Chlorothiazide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Glipizide (Compound)
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glipizide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Chlorothiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide |
DB00018 | DB11995 | 199 | 1,634 | [
"DDInter945",
"DDInter143"
] | Interferon alfa-n3 | Avatrombopag | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require platelet transfusions before surgical procedures to decrease the risk of bleeding. Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy. Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. It is administered orally as the salt form avatrombopag maleate. _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by increasing platelet counts to the optimal level ≥50,000 per microliter. | Moderate | 1 | [
[
[
199,
24,
1634
]
],
[
[
199,
23,
450
],
[
450,
62,
367
],
[
367,
24,
1634
]
],
[
[
199,
24,
1662
],
[
1662,
63,
342
],
[
342,
24,
1634
]
],
[
[
199,
23,
450
],
[
450,
24,
851
],
[
851,
24,
1634
]
],
[
[
199,
24,
4
],
[
4,
24,
350
],
[
350,
25,
1634
]
],
[
[
199,
23,
450
],
[
450,
23,
697
],
[
697,
24,
1634
]
],
[
[
199,
24,
1503
],
[
1503,
24,
1613
],
[
1613,
24,
1634
]
],
[
[
199,
23,
450
],
[
450,
63,
254
],
[
254,
24,
1634
]
],
[
[
199,
24,
1031
],
[
1031,
23,
915
],
[
915,
24,
1634
]
],
[
[
199,
24,
270
],
[
270,
63,
350
],
[
350,
25,
1634
]
]
] | [
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon gamma-1b"
],
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avatrombopag"
]
]
] | Interferon alfa-n3 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Interferon gamma-1b and Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon alfa-n3 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Avatrombopag
Interferon alfa-n3 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon alfa-n3 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Avatrombopag |
DB00046 | DB13007 | 1,179 | 1,060 | [
"DDInter940",
"DDInter642"
] | Insulin lispro | Enfortumab vedotin | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022. | Moderate | 1 | [
[
[
1179,
24,
1060
]
],
[
[
1179,
24,
590
],
[
590,
24,
1060
]
],
[
[
1179,
24,
1385
],
[
1385,
63,
1060
]
],
[
[
1179,
24,
609
],
[
609,
25,
1060
]
],
[
[
1179,
24,
590
],
[
590,
24,
1604
],
[
1604,
23,
1060
]
],
[
[
1179,
24,
1645
],
[
1645,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
1179,
24,
52
],
[
52,
63,
590
],
[
590,
24,
1060
]
],
[
[
1179,
24,
1450
],
[
1450,
63,
129
],
[
129,
23,
1060
]
],
[
[
1179,
24,
168
],
[
168,
25,
1604
],
[
1604,
23,
1060
]
],
[
[
1179,
24,
1344
],
[
1344,
40,
549
],
[
549,
24,
1060
]
]
] | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
]
] | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Enfortumab vedotin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin |
DB00342 | DB12332 | 1,181 | 1,619 | [
"DDInter1770",
"DDInter1626"
] | Terfenadine | Rucaparib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1181,
24,
1619
]
],
[
[
1181,
24,
307
],
[
307,
23,
1619
]
],
[
[
1181,
23,
112
],
[
112,
23,
1619
]
],
[
[
1181,
24,
87
],
[
87,
24,
1619
]
],
[
[
1181,
63,
1100
],
[
1100,
24,
1619
]
],
[
[
1181,
25,
1662
],
[
1662,
24,
1619
]
],
[
[
1181,
24,
159
],
[
159,
63,
1619
]
],
[
[
1181,
64,
215
],
[
215,
24,
1619
]
],
[
[
1181,
23,
1247
],
[
1247,
24,
1619
]
],
[
[
1181,
25,
1375
],
[
1375,
63,
1619
]
]
] | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
]
] | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Terfenadine may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Terfenadine may lead to a major life threatening interaction when taken with Indinavir and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Terfenadine may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB00281 | DB00612 | 608 | 1,121 | [
"DDInter1066",
"DDInter216"
] | Lidocaine | Bisoprolol | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. | Moderate | 1 | [
[
[
608,
24,
1121
]
],
[
[
608,
24,
819
],
[
819,
40,
1121
]
],
[
[
608,
63,
88
],
[
88,
40,
1121
]
],
[
[
608,
6,
12523
],
[
12523,
45,
1121
]
],
[
[
608,
21,
28783
],
[
28783,
60,
1121
]
],
[
[
608,
25,
497
],
[
497,
63,
1121
]
],
[
[
608,
63,
966
],
[
966,
24,
1121
]
],
[
[
608,
24,
1446
],
[
1446,
63,
1121
]
],
[
[
608,
23,
1220
],
[
1220,
63,
1121
]
],
[
[
608,
24,
1010
],
[
1010,
24,
1121
]
]
] | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Oropharyngeal pain"
],
[
"Oropharyngeal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
],
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
]
] | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Bisoprolol (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Bisoprolol (Compound)
Lidocaine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bisoprolol (Compound)
Lidocaine (Compound) causes Oropharyngeal pain (Side Effect) and Oropharyngeal pain (Side Effect) is caused by Bisoprolol (Compound)
Lidocaine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol |
DB00016 | DB01197 | 787 | 1,603 | [
"DDInter671",
"DDInter292"
] | Erythropoietin | Captopril | Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label]. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropo | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension. | Minor | 0 | [
[
[
787,
23,
1603
]
],
[
[
787,
23,
610
],
[
610,
1,
1603
]
],
[
[
787,
23,
1058
],
[
1058,
40,
610
],
[
610,
1,
1603
]
],
[
[
787,
23,
610
],
[
610,
5,
11576
],
[
11576,
44,
1603
]
],
[
[
787,
23,
1058
],
[
1058,
6,
9118
],
[
9118,
45,
1603
]
],
[
[
787,
23,
610
],
[
610,
18,
2488
],
[
2488,
45,
1603
]
],
[
[
787,
23,
1638
],
[
1638,
1,
610
],
[
610,
1,
1603
]
],
[
[
787,
23,
1058
],
[
1058,
18,
9275
],
[
9275,
57,
1603
]
],
[
[
787,
24,
687
],
[
687,
63,
20
],
[
20,
24,
1603
]
],
[
[
787,
23,
1058
],
[
1058,
23,
1475
],
[
1475,
62,
1603
]
]
] | [
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is treated by {v} (Compound)",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} (Compound) binds {v} (Gene)",
"ACE"
],
[
"ACE",
"{u} (Gene) is bound by {v} (Compound)",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) downregulates {v} (Gene)",
"MMP2"
],
[
"MMP2",
"{u} (Gene) is bound by {v} (Compound)",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trandolapril"
],
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} (Compound) downregulates {v} (Gene)",
"RNF167"
],
[
"RNF167",
"{u} (Gene) is downregulated by {v} (Compound)",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conestat alfa"
],
[
"Conestat alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Captopril"
]
]
] | Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Moexipril and Moexipril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Captopril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Enalapril and Enalapril (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Captopril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Moexipril and Moexipril (Compound) binds ACE (Gene) and ACE (Gene) is bound by Captopril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Enalapril and Enalapril (Compound) downregulates MMP2 (Gene) and MMP2 (Gene) is bound by Captopril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Trandolapril and Trandolapril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Captopril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Moexipril and Moexipril (Compound) downregulates RNF167 (Gene) and RNF167 (Gene) is downregulated by Captopril (Compound)
Erythropoietin may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa and Conestat alfa may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Moexipril and Moexipril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate and Sodium citrate may cause a minor interaction that can limit clinical effects when taken with Captopril |
DB00208 | DB11642 | 1,018 | 938 | [
"DDInter1804",
"DDInter1480"
] | Ticlopidine | Pitolisant | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Moderate | 1 | [
[
[
1018,
24,
938
]
],
[
[
1018,
24,
752
],
[
752,
24,
938
]
],
[
[
1018,
23,
870
],
[
870,
24,
938
]
],
[
[
1018,
25,
477
],
[
477,
24,
938
]
],
[
[
1018,
25,
1421
],
[
1421,
63,
938
]
],
[
[
1018,
24,
283
],
[
283,
63,
938
]
],
[
[
1018,
25,
39
],
[
39,
25,
938
]
],
[
[
1018,
24,
593
],
[
593,
25,
938
]
],
[
[
1018,
24,
752
],
[
752,
23,
112
],
[
112,
23,
938
]
],
[
[
1018,
24,
254
],
[
254,
24,
760
],
[
760,
24,
938
]
]
] | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pitolisant"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
]
] | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Ticlopidine may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Ticlopidine may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Ticlopidine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Pitolisant
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Pitolisant
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant |
DB00454 | DB00501 | 1,349 | 752 | [
"DDInter1150",
"DDInter380"
] | Meperidine | Cimetidine | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Moderate | 1 | [
[
[
1349,
24,
752
]
],
[
[
1349,
6,
8374
],
[
8374,
45,
752
]
],
[
[
1349,
21,
28778
],
[
28778,
60,
752
]
],
[
[
1349,
24,
256
],
[
256,
62,
752
]
],
[
[
1349,
25,
1166
],
[
1166,
62,
752
]
],
[
[
1349,
40,
411
],
[
411,
63,
752
]
],
[
[
1349,
24,
1362
],
[
1362,
63,
752
]
],
[
[
1349,
64,
475
],
[
475,
24,
752
]
],
[
[
1349,
25,
1264
],
[
1264,
63,
752
]
],
[
[
1349,
63,
352
],
[
352,
24,
752
]
]
] | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
],
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
]
] | Meperidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cimetidine (Compound)
Meperidine (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Cimetidine (Compound)
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Meperidine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Meperidine (Compound) resembles Remifentanil (Compound) and Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Meperidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Meperidine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine |
DB09312 | DB11248 | 967 | 1,193 | [
"DDInter106",
"DDInter1965"
] | Antithymocyte immunoglobulin (rabbit) | Zinc gluconate | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells. | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. Although it has been nasally administered for treating the common cold, this route of administration has been associated with some cases of anosmia , , , . Studies show that zinc may be better absorbed in humans in the gluconate form , , however, results from other studies may vary.[A27280, L2082] Interestingly, zinc supplementation has become a critical intervention for treating diarrheal episodes in children. Studies suggest that administration of zinc along with new low osmolarity oral rehydration solutions/salts (oral rehydration solution), may reduce both the duration and severity of diarrheal episodes for up to 12 weeks . More information about Zinc (in its natural form) is available at . | Minor | 0 | [
[
[
967,
23,
1193
]
],
[
[
967,
24,
1531
],
[
1531,
23,
1193
]
],
[
[
967,
24,
270
],
[
270,
62,
1193
]
],
[
[
967,
63,
66
],
[
66,
23,
1193
]
],
[
[
967,
25,
1259
],
[
1259,
62,
1193
]
],
[
[
967,
64,
908
],
[
908,
23,
1193
]
],
[
[
967,
25,
976
],
[
976,
23,
1193
]
],
[
[
967,
64,
1292
],
[
1292,
24,
1193
]
],
[
[
967,
24,
1531
],
[
1531,
63,
1096
],
[
1096,
23,
1193
]
],
[
[
967,
63,
66
],
[
66,
24,
1096
],
[
1096,
23,
1193
]
]
] | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
]
] | Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate |
DB00574 | DB09241 | 121 | 1,629 | [
"DDInter717",
"DDInter1186"
] | Fenfluramine | Methylene blue | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Major | 2 | [
[
[
121,
25,
1629
]
],
[
[
121,
24,
1052
],
[
1052,
24,
1629
]
],
[
[
121,
24,
1032
],
[
1032,
63,
1629
]
],
[
[
121,
64,
73
],
[
73,
25,
1629
]
],
[
[
121,
25,
851
],
[
851,
25,
1629
]
],
[
[
121,
24,
1359
],
[
1359,
25,
1629
]
],
[
[
121,
63,
576
],
[
576,
25,
1629
]
],
[
[
121,
25,
858
],
[
858,
64,
1629
]
],
[
[
121,
24,
180
],
[
180,
64,
1629
]
],
[
[
121,
24,
1052
],
[
1052,
24,
1148
],
[
1148,
24,
1629
]
]
] | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
],
[
"Dezocine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esketamine"
],
[
"Esketamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
]
] | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Fenfluramine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Methylene blue
Fenfluramine may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone may lead to a major life threatening interaction when taken with Methylene blue
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine may lead to a major life threatening interaction when taken with Methylene blue
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may lead to a major life threatening interaction when taken with Methylene blue
Fenfluramine may lead to a major life threatening interaction when taken with Esketamine and Esketamine may lead to a major life threatening interaction when taken with Methylene blue
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may lead to a major life threatening interaction when taken with Methylene blue
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue |
DB00358 | DB00543 | 1,010 | 87 | [
"DDInter1140",
"DDInter82"
] | Mefloquine | Amoxapine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation. | Moderate | 1 | [
[
[
1010,
24,
87
]
],
[
[
1010,
24,
623
],
[
623,
40,
87
]
],
[
[
1010,
25,
695
],
[
695,
40,
87
]
],
[
[
1010,
63,
867
],
[
867,
1,
87
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
87
]
],
[
[
1010,
7,
1986
],
[
1986,
46,
87
]
],
[
[
1010,
21,
28852
],
[
28852,
60,
87
]
],
[
[
1010,
23,
112
],
[
112,
62,
87
]
],
[
[
1010,
24,
1619
],
[
1619,
63,
87
]
],
[
[
1010,
24,
1424
],
[
1424,
24,
87
]
]
] | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} (Compound) upregulates {v} (Gene)",
"INSIG1"
],
[
"INSIG1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
]
] | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Mefloquine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Amoxapine (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine (Compound) resembles Amoxapine (Compound)
Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Amoxapine (Compound)
Mefloquine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Amoxapine (Compound)
Mefloquine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Amoxapine (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amoxapine
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine |
DB00341 | DB00777 | 1,242 | 146 | [
"DDInter343",
"DDInter1537"
] | Cetirizine | Propiomazine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects. Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. | Moderate | 1 | [
[
[
1242,
24,
146
]
],
[
[
1242,
24,
508
],
[
508,
1,
146
]
],
[
[
1242,
24,
401
],
[
401,
63,
146
]
],
[
[
1242,
24,
1301
],
[
1301,
40,
146
]
],
[
[
1242,
63,
576
],
[
576,
1,
146
]
],
[
[
1242,
1,
1321
],
[
1321,
40,
146
]
],
[
[
1242,
6,
10104
],
[
10104,
45,
146
]
],
[
[
1242,
24,
1233
],
[
1233,
24,
146
]
],
[
[
1242,
74,
701
],
[
701,
24,
146
]
],
[
[
1242,
63,
1648
],
[
1648,
24,
146
]
]
] | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound)",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
]
] | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Propiomazine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Propiomazine (Compound)
Cetirizine (Compound) resembles Prochlorperazine (Compound) and Prochlorperazine (Compound) resembles Propiomazine (Compound)
Cetirizine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Propiomazine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine |
DB00443 | DB14730 | 251 | 1,412 | [
"DDInter195",
"DDInter264"
] | Betamethasone | Calaspargase pegol | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
251,
24,
1412
]
],
[
[
251,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
251,
63,
1647
],
[
1647,
24,
1412
]
],
[
[
251,
1,
175
],
[
175,
24,
1412
]
],
[
[
251,
62,
1018
],
[
1018,
24,
1412
]
],
[
[
251,
25,
593
],
[
593,
24,
1412
]
],
[
[
251,
64,
581
],
[
581,
24,
1412
]
],
[
[
251,
40,
167
],
[
167,
24,
1412
]
],
[
[
251,
25,
770
],
[
770,
25,
1412
]
],
[
[
251,
63,
1101
],
[
1101,
25,
1412
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Betamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Betamethasone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Betamethasone may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Betamethasone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Calaspargase pegol |
DB00808 | DB09134 | 1,605 | 1,552 | [
"DDInter916",
"DDInter966"
] | Indapamide | Ioversol | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol, enhances the contrast between vessels in the path of the flow of the contrast medium and normal tissue, allowing the visualization of internal structures. Ioversol is a highly hydrophilic agent considered to be generally safe; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol, which is only indicated for intra-arterial and intravenous use. Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left ventriculography.[L41780,L41790] | Moderate | 1 | [
[
[
1605,
24,
1552
]
],
[
[
1605,
40,
811
],
[
811,
24,
1552
]
],
[
[
1605,
63,
1648
],
[
1648,
24,
1552
]
],
[
[
1605,
24,
848
],
[
848,
25,
1552
]
],
[
[
1605,
63,
1274
],
[
1274,
25,
1552
]
],
[
[
1605,
40,
811
],
[
811,
63,
1648
],
[
1648,
24,
1552
]
],
[
[
1605,
63,
1648
],
[
1648,
24,
819
],
[
819,
24,
1552
]
],
[
[
1605,
24,
848
],
[
848,
24,
819
],
[
819,
24,
1552
]
],
[
[
1605,
63,
1287
],
[
1287,
25,
33
],
[
33,
24,
1552
]
],
[
[
1605,
63,
1645
],
[
1645,
63,
228
],
[
228,
24,
1552
]
]
] | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
]
] | Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Ioversol
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Ioversol
Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Dofetilide and Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Ioversol |
DB00065 | DB00549 | 581 | 522 | [
"DDInter923",
"DDInter1955"
] | Infliximab | Zafirlukast | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Moderate | 1 | [
[
[
581,
24,
522
]
],
[
[
581,
25,
168
],
[
168,
24,
522
]
],
[
[
581,
25,
1488
],
[
1488,
63,
522
]
],
[
[
581,
24,
267
],
[
267,
63,
522
]
],
[
[
581,
63,
491
],
[
491,
24,
522
]
],
[
[
581,
24,
367
],
[
367,
24,
522
]
],
[
[
581,
64,
1057
],
[
1057,
24,
522
]
],
[
[
581,
25,
990
],
[
990,
64,
522
]
],
[
[
581,
24,
704
],
[
704,
64,
522
]
],
[
[
581,
25,
168
],
[
168,
6,
7950
],
[
7950,
45,
522
]
]
] | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zafirlukast"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Zafirlukast"
]
]
] | Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Infliximab may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Infliximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Infliximab may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Zafirlukast
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl may lead to a major life threatening interaction when taken with Zafirlukast
Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Zafirlukast (Compound) |
DB01138 | DB06605 | 804 | 1,409 | [
"DDInter1726",
"DDInter108"
] | Sulfinpyrazone | Apixaban | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Major | 2 | [
[
[
804,
25,
1409
]
],
[
[
804,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
804,
24,
1670
],
[
1670,
63,
1409
]
],
[
[
804,
63,
723
],
[
723,
24,
1409
]
],
[
[
804,
62,
1101
],
[
1101,
24,
1409
]
],
[
[
804,
24,
392
],
[
392,
24,
1409
]
],
[
[
804,
25,
235
],
[
235,
64,
1409
]
],
[
[
804,
63,
1061
],
[
1061,
25,
1409
]
],
[
[
804,
24,
39
],
[
39,
25,
1409
]
],
[
[
804,
25,
1213
],
[
1213,
25,
1409
]
]
] | [
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
]
] | Sulfinpyrazone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sulfinpyrazone may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Apixaban
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may lead to a major life threatening interaction when taken with Apixaban
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Apixaban
Sulfinpyrazone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Apixaban |
DB00092 | DB00970 | 58 | 0 | [
"DDInter40",
"DDInter466"
] | Alefacept | Dactinomycin | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | Moderate | 1 | [
[
[
58,
24,
0
]
],
[
[
58,
24,
259
],
[
259,
63,
0
]
],
[
[
58,
63,
1184
],
[
1184,
24,
0
]
],
[
[
58,
23,
1461
],
[
1461,
24,
0
]
],
[
[
58,
24,
611
],
[
611,
24,
0
]
],
[
[
58,
25,
1377
],
[
1377,
64,
0
]
],
[
[
58,
24,
375
],
[
375,
64,
0
]
],
[
[
58,
63,
1057
],
[
1057,
25,
0
]
],
[
[
58,
25,
1066
],
[
1066,
25,
0
]
],
[
[
58,
24,
259
],
[
259,
24,
384
],
[
384,
63,
0
]
]
] | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dactinomycin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
]
] | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Alefacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Dactinomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Dactinomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Dactinomycin
Alefacept may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Dactinomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin |
DB00443 | DB00495 | 251 | 139 | [
"DDInter195",
"DDInter1961"
] | Betamethasone | Zidovudine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] | Moderate | 1 | [
[
[
251,
24,
139
]
],
[
[
251,
24,
1477
],
[
1477,
40,
139
]
],
[
[
251,
6,
8374
],
[
8374,
45,
139
]
],
[
[
251,
21,
29209
],
[
29209,
60,
139
]
],
[
[
251,
24,
609
],
[
609,
62,
139
]
],
[
[
251,
63,
599
],
[
599,
24,
139
]
],
[
[
251,
40,
870
],
[
870,
63,
139
]
],
[
[
251,
24,
1017
],
[
1017,
63,
139
]
],
[
[
251,
1,
617
],
[
617,
63,
139
]
],
[
[
251,
25,
770
],
[
770,
63,
139
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} (Compound) resembles {v} (Compound)",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Zidovudine (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zidovudine (Compound)
Betamethasone (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Zidovudine (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Zidovudine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Betamethasone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Betamethasone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine |
DB00477 | DB08871 | 216 | 36 | [
"DDInter363",
"DDInter666"
] | Chlorpromazine | Eribulin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors . | Moderate | 1 | [
[
[
216,
24,
36
]
],
[
[
216,
63,
1424
],
[
1424,
24,
36
]
],
[
[
216,
35,
820
],
[
820,
24,
36
]
],
[
[
216,
24,
1674
],
[
1674,
24,
36
]
],
[
[
216,
40,
9
],
[
9,
24,
36
]
],
[
[
216,
24,
28
],
[
28,
63,
36
]
],
[
[
216,
1,
1237
],
[
1237,
24,
36
]
],
[
[
216,
25,
351
],
[
351,
63,
36
]
],
[
[
216,
23,
112
],
[
112,
24,
36
]
],
[
[
216,
25,
1593
],
[
1593,
25,
36
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
]
] | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Chlorpromazine (Compound) resembles Alimemazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Chlorpromazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Chlorpromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Chlorpromazine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Chlorpromazine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Eribulin |
DB00906 | DB01069 | 1,567 | 401 | [
"DDInter1801",
"DDInter1533"
] | Tiagabine | Promethazine | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
1567,
24,
401
]
],
[
[
1567,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1567,
21,
28709
],
[
28709,
60,
401
]
],
[
[
1567,
63,
701
],
[
701,
24,
401
]
],
[
[
1567,
24,
770
],
[
770,
24,
401
]
],
[
[
1567,
24,
1487
],
[
1487,
64,
401
]
],
[
[
1567,
24,
1264
],
[
1264,
63,
146
],
[
146,
24,
401
]
],
[
[
1567,
24,
820
],
[
820,
40,
11245
],
[
11245,
1,
401
]
],
[
[
1567,
24,
649
],
[
649,
1,
11275
],
[
11275,
40,
401
]
],
[
[
1567,
21,
28709
],
[
28709,
60,
1264
],
[
1264,
63,
401
]
]
] | [
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Ethopropazine"
],
[
"Ethopropazine",
"{u} (Compound) resembles {v} (Compound)",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} (Compound) resembles {v} (Compound)",
"Promethazine"
]
],
[
[
"Tiagabine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
]
] | Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tiagabine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound)
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Promethazine
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Ethopropazine (Compound) and Ethopropazine (Compound) resembles Promethazine (Compound)
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Promethazine (Compound)
Tiagabine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine |
DB00047 | DB00678 | 176 | 240 | [
"DDInter932",
"DDInter1095"
] | Insulin glargine | Losartan | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis. Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide]. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995. | Moderate | 1 | [
[
[
176,
24,
240
]
],
[
[
176,
24,
1414
],
[
1414,
1,
240
]
],
[
[
176,
24,
911
],
[
911,
40,
240
]
],
[
[
176,
24,
870
],
[
870,
63,
240
]
],
[
[
176,
24,
999
],
[
999,
24,
240
]
],
[
[
176,
23,
948
],
[
948,
64,
240
]
],
[
[
176,
24,
1414
],
[
1414,
5,
11590
],
[
11590,
44,
240
]
],
[
[
176,
24,
217
],
[
217,
1,
11292
],
[
11292,
40,
240
]
],
[
[
176,
24,
911
],
[
911,
40,
11292
],
[
11292,
40,
240
]
],
[
[
176,
24,
870
],
[
870,
24,
1414
],
[
1414,
1,
240
]
]
] | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
],
[
"Eprosartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
],
[
"Azilsartan medoxomil",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium gluconate"
],
[
"Potassium gluconate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
],
[
"Eprosartan",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
],
[
"Olmesartan",
"{u} (Compound) resembles {v} (Compound)",
"Candesartan"
],
[
"Candesartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
],
[
"Azilsartan medoxomil",
"{u} (Compound) resembles {v} (Compound)",
"Candesartan"
],
[
"Candesartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
],
[
"Eprosartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
]
]
] | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan and Eprosartan (Compound) resembles Losartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Losartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Losartan
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Losartan
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate and Potassium gluconate may lead to a major life threatening interaction when taken with Losartan
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan and Eprosartan (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Losartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Candesartan (Compound) and Candesartan (Compound) resembles Losartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Candesartan (Compound) and Candesartan (Compound) resembles Losartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan and Eprosartan (Compound) resembles Losartan (Compound) |
DB06699 | DB14509 | 774 | 1,399 | [
"DDInter493",
"DDInter1081"
] | Degarelix | Lithium carbonate | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
774,
24,
1399
]
],
[
[
774,
63,
820
],
[
820,
24,
1399
]
],
[
[
774,
24,
927
],
[
927,
24,
1399
]
],
[
[
774,
40,
521
],
[
521,
24,
1399
]
],
[
[
774,
62,
112
],
[
112,
24,
1399
]
],
[
[
774,
64,
1425
],
[
1425,
25,
1399
]
],
[
[
774,
25,
351
],
[
351,
25,
1399
]
],
[
[
774,
25,
982
],
[
982,
64,
1399
]
],
[
[
774,
63,
1133
],
[
1133,
25,
1399
]
],
[
[
774,
63,
820
],
[
820,
63,
874
],
[
874,
23,
1399
]
]
] | [
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} (Compound) resembles {v} (Compound)",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
]
] | Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Degarelix (Compound) resembles Goserelin (Compound) and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Degarelix may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Lithium carbonate
Degarelix may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Lithium carbonate
Degarelix may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lithium carbonate
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Lithium carbonate
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate |
DB00191 | DB00988 | 73 | 817 | [
"DDInter1447",
"DDInter584"
] | Phentermine | Dopamine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. | Moderate | 1 | [
[
[
73,
24,
817
]
],
[
[
73,
24,
532
],
[
532,
1,
817
]
],
[
[
73,
24,
1148
],
[
1148,
63,
817
]
],
[
[
73,
24,
874
],
[
874,
40,
817
]
],
[
[
73,
6,
8774
],
[
8774,
45,
817
]
],
[
[
73,
21,
28722
],
[
28722,
60,
817
]
],
[
[
73,
24,
1674
],
[
1674,
24,
817
]
],
[
[
73,
25,
1466
],
[
1466,
24,
817
]
],
[
[
73,
25,
222
],
[
222,
63,
817
]
],
[
[
73,
63,
1685
],
[
1685,
24,
817
]
]
] | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
],
[
"Dobutamine",
"{u} (Compound) resembles {v} (Compound)",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} (Compound) binds {v} (Gene)",
"MAOB"
],
[
"MAOB",
"{u} (Gene) is bound by {v} (Compound)",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
]
] | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Dopamine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Dopamine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Dopamine (Compound)
Phentermine (Compound) binds MAOB (Gene) and MAOB (Gene) is bound by Dopamine (Compound)
Phentermine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dopamine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Dopamine
Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Dopamine
Phentermine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Dopamine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Dopamine |
DB00685 | DB09104 | 1,299 | 286 | [
"DDInter1887",
"DDInter1118"
] | Trovafloxacin | Magnesium hydroxide | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
1299,
24,
286
]
],
[
[
1299,
23,
60
],
[
60,
23,
286
]
],
[
[
1299,
24,
848
],
[
848,
23,
286
]
],
[
[
1299,
24,
1283
],
[
1283,
24,
286
]
],
[
[
1299,
25,
891
],
[
891,
24,
286
]
],
[
[
1299,
25,
1019
],
[
1019,
63,
286
]
],
[
[
1299,
64,
251
],
[
251,
24,
286
]
],
[
[
1299,
24,
428
],
[
428,
63,
286
]
],
[
[
1299,
1,
739
],
[
739,
24,
286
]
],
[
[
1299,
23,
613
],
[
613,
24,
286
]
]
] | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
]
] | Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Trovafloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Trovafloxacin may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Trovafloxacin may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Trovafloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide |
DB00261 | DB00661 | 702 | 122 | [
"DDInter93",
"DDInter1928"
] | Anagrelide | Verapamil | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate. | Moderate | 1 | [
[
[
702,
24,
122
]
],
[
[
702,
6,
7950
],
[
7950,
45,
122
]
],
[
[
702,
21,
28809
],
[
28809,
60,
122
]
],
[
[
702,
24,
222
],
[
222,
62,
122
]
],
[
[
702,
25,
36
],
[
36,
62,
122
]
],
[
[
702,
24,
1512
],
[
1512,
23,
122
]
],
[
[
702,
24,
723
],
[
723,
63,
122
]
],
[
[
702,
25,
1619
],
[
1619,
63,
122
]
],
[
[
702,
24,
1031
],
[
1031,
24,
122
]
],
[
[
702,
64,
600
],
[
600,
24,
122
]
]
] | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
]
] | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Verapamil (Compound)
Anagrelide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Verapamil (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Verapamil
Anagrelide may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a minor interaction that can limit clinical effects when taken with Verapamil
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Verapamil
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Verapamil
Anagrelide may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Verapamil
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Verapamil
Anagrelide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Verapamil |
DB01229 | DB11003 | 973 | 748 | [
"DDInter1378",
"DDInter100"
] | Paclitaxel (protein-bound) | Anthrax vaccine | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
973,
24,
748
]
],
[
[
973,
63,
168
],
[
168,
24,
748
]
],
[
[
973,
25,
676
],
[
676,
63,
748
]
],
[
[
973,
24,
1683
],
[
1683,
24,
748
]
],
[
[
973,
24,
1619
],
[
1619,
63,
748
]
],
[
[
973,
64,
1057
],
[
1057,
24,
748
]
],
[
[
973,
25,
1011
],
[
1011,
24,
748
]
],
[
[
973,
63,
168
],
[
168,
24,
322
],
[
322,
24,
748
]
],
[
[
973,
63,
896
],
[
896,
63,
322
],
[
322,
24,
748
]
],
[
[
973,
25,
676
],
[
676,
64,
322
],
[
322,
24,
748
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB06650 | DB14783 | 1,500 | 287 | [
"DDInter1324",
"DDInter574"
] | Ofatumumab | Diroximel fumarate | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD- | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
1500,
24,
287
]
],
[
[
1500,
63,
599
],
[
599,
24,
287
]
],
[
[
1500,
24,
270
],
[
270,
24,
287
]
],
[
[
1500,
25,
1510
],
[
1510,
25,
287
]
],
[
[
1500,
64,
1066
],
[
1066,
25,
287
]
],
[
[
1500,
25,
676
],
[
676,
64,
287
]
],
[
[
1500,
24,
713
],
[
713,
25,
287
]
],
[
[
1500,
63,
599
],
[
599,
24,
1101
],
[
1101,
24,
287
]
],
[
[
1500,
24,
270
],
[
270,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1500,
63,
259
],
[
259,
63,
1101
],
[
1101,
24,
287
]
]
] | [
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
]
] | Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ofatumumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Ofatumumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Ofatumumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB01001 | DB01579 | 688 | 341 | [
"DDInter1632",
"DDInter1439"
] | Salbutamol | Phendimetrazine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
688,
24,
341
]
],
[
[
688,
21,
28662
],
[
28662,
60,
341
]
],
[
[
688,
24,
959
],
[
959,
24,
341
]
],
[
[
688,
24,
1281
],
[
1281,
63,
341
]
],
[
[
688,
63,
127
],
[
127,
24,
341
]
],
[
[
688,
63,
121
],
[
121,
25,
341
]
],
[
[
688,
24,
1053
],
[
1053,
25,
341
]
],
[
[
688,
64,
290
],
[
290,
25,
341
]
],
[
[
688,
24,
1629
],
[
1629,
64,
341
]
],
[
[
688,
21,
28662
],
[
28662,
60,
111
],
[
111,
1,
341
]
]
] | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Salbutamol",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} (Compound) resembles {v} (Compound)",
"Phendimetrazine"
]
]
] | Salbutamol (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Phendimetrazine (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Phendimetrazine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Phendimetrazine
Salbutamol may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Phendimetrazine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Phendimetrazine
Salbutamol (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Tranylcypromine (Compound) and Tranylcypromine (Compound) resembles Phendimetrazine (Compound) |
DB00396 | DB14568 | 989 | 982 | [
"DDInter1529",
"DDInter1000"
] | Progesterone | Ivosidenib | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization, as well as in other formulations to promote and support pregnancy. Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone. Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin [FDA label]. Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes [Label,F389 | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Moderate | 1 | [
[
[
989,
24,
982
]
],
[
[
989,
63,
1101
],
[
1101,
23,
982
]
],
[
[
989,
24,
1409
],
[
1409,
24,
982
]
],
[
[
989,
25,
1456
],
[
1456,
24,
982
]
],
[
[
989,
1,
566
],
[
566,
24,
982
]
],
[
[
989,
24,
159
],
[
159,
63,
982
]
],
[
[
989,
63,
600
],
[
600,
25,
982
]
],
[
[
989,
24,
1213
],
[
1213,
25,
982
]
],
[
[
989,
63,
1101
],
[
1101,
23,
271
],
[
271,
23,
982
]
],
[
[
989,
24,
1409
],
[
1409,
63,
1101
],
[
1101,
23,
982
]
]
] | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
],
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
]
] | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Progesterone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Progesterone (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Ivosidenib
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib |
DB00726 | DB01211 | 1,164 | 609 | [
"DDInter1876",
"DDInter393"
] | Trimipramine | Clarithromycin | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
1164,
24,
609
]
],
[
[
1164,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1164,
7,
8733
],
[
8733,
57,
609
]
],
[
[
1164,
21,
28662
],
[
28662,
60,
609
]
],
[
[
1164,
63,
600
],
[
600,
23,
609
]
],
[
[
1164,
25,
222
],
[
222,
23,
609
]
],
[
[
1164,
23,
112
],
[
112,
23,
609
]
],
[
[
1164,
24,
770
],
[
770,
24,
609
]
],
[
[
1164,
24,
1383
],
[
1383,
63,
609
]
],
[
[
1164,
63,
322
],
[
322,
24,
609
]
]
] | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} (Compound) upregulates {v} (Gene)",
"PHGDH"
],
[
"PHGDH",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
]
] | Trimipramine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Trimipramine (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Clarithromycin (Compound)
Trimipramine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Trimipramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00590 | DB00860 | 1,433 | 891 | [
"DDInter592",
"DDInter1513"
] | Doxazosin | Prednisolone | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1433,
24,
891
]
],
[
[
1433,
24,
175
],
[
175,
40,
891
]
],
[
[
1433,
24,
167
],
[
167,
1,
891
]
],
[
[
1433,
63,
251
],
[
251,
1,
891
]
],
[
[
1433,
6,
4973
],
[
4973,
45,
891
]
],
[
[
1433,
21,
29232
],
[
29232,
60,
891
]
],
[
[
1433,
24,
384
],
[
384,
63,
891
]
],
[
[
1433,
1,
1205
],
[
1205,
24,
891
]
],
[
[
1433,
40,
195
],
[
195,
63,
891
]
],
[
[
1433,
63,
1648
],
[
1648,
24,
891
]
]
] | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Prazosin"
],
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Terazosin"
],
[
"Terazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
]
] | Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Prednisolone (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisolone (Compound)
Doxazosin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Prednisolone (Compound)
Doxazosin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Prednisolone (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone
Doxazosin (Compound) resembles Prazosin (Compound) and Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone
Doxazosin (Compound) resembles Terazosin (Compound) and Terazosin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone |
DB06043 | DB11627 | 1,644 | 1,367 | [
"DDInter1328",
"DDInter860"
] | Olaratumab | Hepatitis B Vaccine (Recombinant) | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups. In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use). In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma. Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis. | Moderate | 1 | [
[
[
1644,
24,
1367
]
],
[
[
1644,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1644,
24,
259
],
[
259,
24,
1367
]
],
[
[
1644,
25,
375
],
[
375,
24,
1367
]
],
[
[
1644,
63,
66
],
[
66,
24,
1367
]
],
[
[
1644,
25,
676
],
[
676,
63,
1367
]
],
[
[
1644,
24,
270
],
[
270,
63,
1367
]
],
[
[
1644,
64,
1064
],
[
1064,
36,
1083
],
[
1083,
24,
1367
]
],
[
[
1644,
24,
259
],
[
259,
63,
1083
],
[
1083,
24,
1367
]
],
[
[
1644,
25,
375
],
[
375,
64,
1083
],
[
1083,
24,
1367
]
]
] | [
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
]
] | Olaratumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Olaratumab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Olaratumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Olaratumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Trifluridine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Olaratumab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) |
DB00691 | DB01377 | 1,058 | 1,283 | [
"DDInter1237",
"DDInter1119"
] | Moexipril | Magnesium oxide | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1058,
23,
1283
]
],
[
[
1058,
40,
743
],
[
743,
23,
1283
]
],
[
[
1058,
24,
167
],
[
167,
23,
1283
]
],
[
[
1058,
63,
1573
],
[
1573,
23,
1283
]
],
[
[
1058,
1,
954
],
[
954,
23,
1283
]
],
[
[
1058,
24,
1479
],
[
1479,
24,
1283
]
],
[
[
1058,
23,
286
],
[
286,
63,
1283
]
],
[
[
1058,
63,
590
],
[
590,
24,
1283
]
],
[
[
1058,
40,
743
],
[
743,
24,
167
],
[
167,
23,
1283
]
],
[
[
1058,
24,
167
],
[
167,
63,
743
],
[
743,
23,
1283
]
]
] | [
[
[
"Moexipril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
]
] | Moexipril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Moexipril (Compound) resembles Quinapril (Compound) and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Moexipril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Moexipril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide |
DB09407 | DB09481 | 853 | 460 | [
"DDInter1114",
"DDInter1113"
] | Magnesium chloride | Magnesium carbonate | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
853,
24,
460
]
],
[
[
853,
63,
1620
],
[
1620,
24,
460
]
],
[
[
853,
24,
255
],
[
255,
63,
460
]
],
[
[
853,
25,
241
],
[
241,
64,
460
]
],
[
[
853,
64,
1459
],
[
1459,
25,
460
]
],
[
[
853,
63,
809
],
[
809,
25,
460
]
],
[
[
853,
63,
1620
],
[
1620,
63,
1252
],
[
1252,
23,
460
]
],
[
[
853,
63,
1467
],
[
1467,
23,
752
],
[
752,
23,
460
]
],
[
[
853,
63,
739
],
[
739,
24,
401
],
[
401,
23,
460
]
],
[
[
853,
63,
246
],
[
246,
25,
401
],
[
401,
23,
460
]
]
] | [
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
],
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolutegravir"
],
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Raltegravir"
],
[
"Raltegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
]
] | Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Magnesium chloride may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Magnesium carbonate
Magnesium chloride may lead to a major life threatening interaction when taken with Dolutegravir and Dolutegravir may lead to a major life threatening interaction when taken with Magnesium carbonate
Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Raltegravir and Raltegravir may lead to a major life threatening interaction when taken with Magnesium carbonate
Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate |
DB06691 | DB11130 | 849 | 407 | [
"DDInter1155",
"DDInter1344"
] | Mepyramine | Opium | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
849,
24,
407
]
],
[
[
849,
63,
409
],
[
409,
24,
407
]
],
[
[
849,
74,
662
],
[
662,
24,
407
]
],
[
[
849,
24,
1580
],
[
1580,
24,
407
]
],
[
[
849,
24,
418
],
[
418,
63,
407
]
],
[
[
849,
64,
1301
],
[
1301,
24,
407
]
],
[
[
849,
63,
551
],
[
551,
25,
407
]
],
[
[
849,
64,
675
],
[
675,
25,
407
]
],
[
[
849,
63,
409
],
[
409,
63,
104
],
[
104,
24,
407
]
],
[
[
849,
63,
558
],
[
558,
24,
662
],
[
662,
24,
407
]
]
] | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
],
[
"Brexanolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
]
] | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepyramine (Compound) resembles Carbinoxamine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone and Brexanolone may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepyramine may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may lead to a major life threatening interaction when taken with Opium
Mepyramine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Opium
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB06210 | DB08873 | 72 | 74 | [
"DDInter631",
"DDInter221"
] | Eltrombopag | Boceprevir | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with , , and . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with , , and as first line therapy for Hepatitis C . Boceprevir, , , and are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with , , and [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed. | Minor | 0 | [
[
[
72,
23,
74
]
],
[
[
72,
25,
412
],
[
412,
63,
74
]
],
[
[
72,
63,
473
],
[
473,
24,
74
]
],
[
[
72,
24,
466
],
[
466,
63,
74
]
],
[
[
72,
24,
850
],
[
850,
24,
74
]
],
[
[
72,
24,
124
],
[
124,
64,
74
]
],
[
[
72,
63,
392
],
[
392,
25,
74
]
],
[
[
72,
24,
1491
],
[
1491,
25,
74
]
],
[
[
72,
25,
412
],
[
412,
63,
1374
],
[
1374,
23,
74
]
],
[
[
72,
63,
473
],
[
473,
6,
8374
],
[
8374,
45,
74
]
]
] | [
[
[
"Eltrombopag",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Boceprevir"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
]
] | Eltrombopag may lead to a major life threatening interaction when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Boceprevir
Eltrombopag may lead to a major life threatening interaction when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound) |
DB00366 | DB00906 | 1,594 | 1,567 | [
"DDInter600",
"DDInter1801"
] | Doxylamine | Tiagabine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Moderate | 1 | [
[
[
1594,
24,
1567
]
],
[
[
1594,
21,
28814
],
[
28814,
60,
1567
]
],
[
[
1594,
24,
530
],
[
530,
24,
1567
]
],
[
[
1594,
24,
537
],
[
537,
63,
1567
]
],
[
[
1594,
74,
701
],
[
701,
24,
1567
]
],
[
[
1594,
35,
128
],
[
128,
24,
1567
]
],
[
[
1594,
63,
1242
],
[
1242,
24,
1567
]
],
[
[
1594,
35,
272
],
[
272,
63,
1567
]
],
[
[
1594,
21,
28814
],
[
28814,
60,
1213
],
[
1213,
63,
1567
]
],
[
[
1594,
21,
28658
],
[
28658,
60,
13
],
[
13,
24,
1567
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Affect lability"
],
[
"Affect lability",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Affect lability"
],
[
"Affect lability",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
]
] | Doxylamine (Compound) causes Affect lability (Side Effect) and Affect lability (Side Effect) is caused by Tiagabine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Doxylamine (Compound) causes Affect lability (Side Effect) and Affect lability (Side Effect) is caused by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Doxylamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cyproheptadine (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine |
DB00264 | DB00295 | 88 | 475 | [
"DDInter1200",
"DDInter1244"
] | Metoprolol | Morphine | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978. | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Moderate | 1 | [
[
[
88,
24,
475
]
],
[
[
88,
6,
12523
],
[
12523,
45,
475
]
],
[
[
88,
21,
28784
],
[
28784,
60,
475
]
],
[
[
88,
24,
22
],
[
22,
62,
475
]
],
[
[
88,
24,
1192
],
[
1192,
63,
475
]
],
[
[
88,
23,
578
],
[
578,
63,
475
]
],
[
[
88,
40,
887
],
[
887,
63,
475
]
],
[
[
88,
1,
819
],
[
819,
63,
475
]
],
[
[
88,
63,
1648
],
[
1648,
24,
475
]
],
[
[
88,
25,
1166
],
[
1166,
63,
475
]
]
] | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Metoprolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
]
] | Metoprolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Morphine (Compound)
Metoprolol (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Morphine (Compound)
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a minor interaction that can limit clinical effects when taken with Morphine
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Metoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Metoprolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Metoprolol may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Morphine |
DB01618 | DB04843 | 776 | 1,511 | [
"DDInter1239",
"DDInter1149"
] | Molindone | Mepenzolate | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283) | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. | Moderate | 1 | [
[
[
776,
24,
1511
]
],
[
[
776,
63,
537
],
[
537,
24,
1511
]
],
[
[
776,
24,
649
],
[
649,
1,
1511
]
],
[
[
776,
24,
1429
],
[
1429,
63,
1511
]
],
[
[
776,
6,
7992
],
[
7992,
45,
1511
]
],
[
[
776,
21,
28898
],
[
28898,
60,
1511
]
],
[
[
776,
64,
475
],
[
475,
24,
1511
]
],
[
[
776,
24,
830
],
[
830,
24,
1511
]
],
[
[
776,
64,
1621
],
[
1621,
25,
1511
]
],
[
[
776,
63,
543
],
[
543,
35,
1511
]
]
] | [
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
],
[
"Aclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepenzolate"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
]
] | Molindone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Mepenzolate (Compound)
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Molindone (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Mepenzolate (Compound)
Molindone (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Mepenzolate (Compound)
Molindone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Molindone may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Mepenzolate
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide (Compound) resembles Mepenzolate (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate |
DB00491 | DB01232 | 127 | 1,327 | [
"DDInter1217",
"DDInter1640"
] | Miglitol | Saquinavir | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] | Moderate | 1 | [
[
[
127,
24,
1327
]
],
[
[
127,
63,
798
],
[
798,
40,
1327
]
],
[
[
127,
24,
915
],
[
915,
40,
1327
]
],
[
[
127,
21,
29665
],
[
29665,
60,
1327
]
],
[
[
127,
24,
222
],
[
222,
23,
1327
]
],
[
[
127,
63,
1685
],
[
1685,
24,
1327
]
],
[
[
127,
24,
303
],
[
303,
24,
1327
]
],
[
[
127,
24,
1040
],
[
1040,
63,
1327
]
],
[
[
127,
24,
820
],
[
820,
64,
1327
]
],
[
[
127,
24,
1674
],
[
1674,
25,
1327
]
]
] | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} (Compound) causes {v} (Side Effect)",
"Intestinal obstruction"
],
[
"Intestinal obstruction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
]
] | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compound)
Miglitol (Compound) causes Intestinal obstruction (Side Effect) and Intestinal obstruction (Side Effect) is caused by Saquinavir (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Saquinavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may lead to a major life threatening interaction when taken with Saquinavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may lead to a major life threatening interaction when taken with Saquinavir |
DB06824 | DB11093 | 29 | 636 | [
"DDInter1864",
"DDInter273"
] | Triethylenetetramine | Calcium citrate | Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease, TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and tolerant to [penicillamine]. TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.[A18804,A19332,A19333,A19334,A19335] | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
29,
24,
636
]
],
[
[
29,
23,
1193
],
[
1193,
63,
246
],
[
246,
24,
636
]
],
[
[
29,
24,
900
],
[
900,
63,
729
],
[
729,
24,
636
]
],
[
[
29,
63,
1283
],
[
1283,
62,
461
],
[
461,
24,
636
]
],
[
[
29,
63,
954
],
[
954,
1,
1523
],
[
1523,
24,
636
]
],
[
[
29,
24,
286
],
[
286,
62,
1482
],
[
1482,
24,
636
]
],
[
[
29,
63,
954
],
[
954,
63,
1572
],
[
1572,
24,
636
]
],
[
[
29,
24,
841
],
[
841,
63,
255
],
[
255,
63,
636
]
],
[
[
29,
23,
1114
],
[
1114,
24,
255
],
[
255,
63,
636
]
],
[
[
29,
63,
1596
],
[
1596,
24,
1436
],
[
1436,
24,
636
]
]
] | [
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
],
[
"Calcium gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
],
[
"Calcium glubionate anhydrous",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
]
] | Triethylenetetramine may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate and Calcium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Digitoxin and Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous and Calcium glubionate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Triethylenetetramine may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate |
DB00285 | DB06788 | 1,100 | 1,616 | [
"DDInter1927",
"DDInter864"
] | Venlafaxine | Histrelin | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007). | Moderate | 1 | [
[
[
1100,
24,
1616
]
],
[
[
1100,
23,
112
],
[
112,
23,
1616
]
],
[
[
1100,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
1100,
24,
603
],
[
603,
63,
1616
]
],
[
[
1100,
63,
1324
],
[
1324,
24,
1616
]
],
[
[
1100,
25,
1264
],
[
1264,
24,
1616
]
],
[
[
1100,
40,
534
],
[
534,
24,
1616
]
],
[
[
1100,
25,
57
],
[
57,
25,
1616
]
],
[
[
1100,
25,
868
],
[
868,
64,
1616
]
],
[
[
1100,
64,
702
],
[
702,
25,
1616
]
]
] | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
]
] | Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Venlafaxine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Venlafaxine (Compound) resembles Tramadol (Compound) and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Venlafaxine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin
Venlafaxine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Histrelin
Venlafaxine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Histrelin |
DB00470 | DB01219 | 530 | 716 | [
"DDInter601",
"DDInter473"
] | Dronabinol | Dantrolene | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
530,
24,
716
]
],
[
[
530,
6,
8374
],
[
8374,
45,
716
]
],
[
[
530,
21,
29316
],
[
29316,
60,
716
]
],
[
[
530,
24,
1609
],
[
1609,
63,
716
]
],
[
[
530,
24,
100
],
[
100,
24,
716
]
],
[
[
530,
63,
13
],
[
13,
24,
716
]
],
[
[
530,
1,
1614
],
[
1614,
24,
716
]
],
[
[
530,
63,
475
],
[
475,
25,
716
]
],
[
[
530,
6,
8374
],
[
8374,
45,
11311
],
[
11311,
1,
716
]
],
[
[
530,
21,
29316
],
[
29316,
60,
11311
],
[
11311,
1,
716
]
]
] | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} (Compound) resembles {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nitrazepam"
],
[
"Nitrazepam",
"{u} (Compound) resembles {v} (Compound)",
"Dantrolene"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nitrazepam"
],
[
"Nitrazepam",
"{u} (Compound) resembles {v} (Compound)",
"Dantrolene"
]
]
] | Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dantrolene (Compound)
Dronabinol (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Dantrolene (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Dantrolene
Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nitrazepam (Compound) and Nitrazepam (Compound) resembles Dantrolene (Compound)
Dronabinol (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Nitrazepam (Compound) and Nitrazepam (Compound) resembles Dantrolene (Compound) |
DB00533 | DB09472 | 1,416 | 1,383 | [
"DDInter1613",
"DDInter1693"
] | Rofecoxib | Sodium sulfate | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2 | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions. | Moderate | 1 | [
[
[
1416,
24,
1383
]
],
[
[
1416,
24,
1613
],
[
1613,
24,
1383
]
],
[
[
1416,
63,
912
],
[
912,
24,
1383
]
],
[
[
1416,
24,
877
],
[
877,
63,
1383
]
],
[
[
1416,
24,
1613
],
[
1613,
63,
609
],
[
609,
24,
1383
]
],
[
[
1416,
24,
477
],
[
477,
25,
609
],
[
609,
24,
1383
]
],
[
[
1416,
63,
912
],
[
912,
24,
609
],
[
609,
24,
1383
]
],
[
[
1416,
24,
848
],
[
848,
63,
1252
],
[
1252,
23,
1383
]
],
[
[
1416,
24,
877
],
[
877,
64,
609
],
[
609,
24,
1383
]
],
[
[
1416,
63,
702
],
[
702,
25,
609
],
[
609,
24,
1383
]
]
] | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
]
] | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate |
DB00760 | DB08880 | 1,584 | 1,510 | [
"DDInter1157",
"DDInter1771"
] | Meropenem | Teriflunomide | Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Moderate | 1 | [
[
[
1584,
24,
1510
]
],
[
[
1584,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
1584,
25,
593
],
[
593,
25,
1510
]
],
[
[
1584,
24,
1096
],
[
1096,
25,
1510
]
],
[
[
1584,
24,
1033
],
[
1033,
64,
129
],
[
129,
63,
1510
]
],
[
[
1584,
25,
593
],
[
593,
64,
608
],
[
608,
23,
1510
]
],
[
[
1584,
21,
29429
],
[
29429,
60,
1398
],
[
1398,
64,
1510
]
],
[
[
1584,
24,
1096
],
[
1096,
62,
1461
],
[
1461,
23,
1510
]
],
[
[
1584,
24,
1033
],
[
1033,
63,
43
],
[
43,
24,
1510
]
],
[
[
1584,
24,
927
],
[
927,
24,
1033
],
[
1033,
63,
1510
]
]
] | [
[
[
"Meropenem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Macitentan"
],
[
"Macitentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melatonin"
],
[
"Melatonin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Meropenem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
]
] | Meropenem may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Meropenem may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Teriflunomide
Meropenem may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may lead to a major life threatening interaction when taken with Teriflunomide
Meropenem may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Meropenem may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Meropenem (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Macitentan (Compound) and Macitentan may lead to a major life threatening interaction when taken with Teriflunomide
Meropenem may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Meropenem may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Melatonin and Melatonin may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Meropenem may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide |
DB00682 | DB01240 | 126 | 885 | [
"DDInter1951",
"DDInter657"
] | Warfarin | Epoprostenol | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
126,
24,
885
]
],
[
[
126,
63,
1061
],
[
1061,
1,
885
]
],
[
[
126,
6,
6017
],
[
6017,
45,
885
]
],
[
[
126,
23,
539
],
[
539,
62,
885
]
],
[
[
126,
64,
1512
],
[
1512,
24,
885
]
],
[
[
126,
63,
1595
],
[
1595,
24,
885
]
],
[
[
126,
24,
1680
],
[
1680,
24,
885
]
],
[
[
126,
24,
972
],
[
972,
63,
885
]
],
[
[
126,
25,
1046
],
[
1046,
63,
885
]
],
[
[
126,
25,
914
],
[
914,
24,
885
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
],
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
],
[
"Choline salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Warfarin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Epoprostenol (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Epoprostenol
Warfarin may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Warfarin may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Warfarin may lead to a major life threatening interaction when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol |
DB00398 | DB08903 | 79 | 996 | [
"DDInter1702",
"DDInter170"
] | Sorafenib | Bedaquiline | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Major | 2 | [
[
[
79,
25,
996
]
],
[
[
79,
6,
8374
],
[
8374,
45,
996
]
],
[
[
79,
21,
29282
],
[
29282,
60,
996
]
],
[
[
79,
23,
112
],
[
112,
23,
996
]
],
[
[
79,
24,
26
],
[
26,
63,
996
]
],
[
[
79,
24,
355
],
[
355,
24,
996
]
],
[
[
79,
63,
912
],
[
912,
24,
996
]
],
[
[
79,
1,
292
],
[
292,
24,
996
]
],
[
[
79,
24,
609
],
[
609,
25,
996
]
],
[
[
79,
25,
1377
],
[
1377,
25,
996
]
]
] | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} (Compound) causes {v} (Side Effect)",
"Arrhythmia"
],
[
"Arrhythmia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} (Compound) resembles {v} (Compound)",
"Regorafenib"
],
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
]
] | Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Sorafenib (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Sorafenib (Compound) resembles Regorafenib (Compound) and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Bedaquiline
Sorafenib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Bedaquiline |
DB01164 | DB12035 | 803 | 943 | [
"DDInter272",
"DDInter1641"
] | Calcium chloride | Sarecycline | Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement. It can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers. | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States . Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne . Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc. | Moderate | 1 | [
[
[
803,
24,
943
]
],
[
[
803,
63,
336
],
[
336,
23,
1135
],
[
1135,
23,
943
]
],
[
[
803,
24,
762
],
[
762,
23,
1135
],
[
1135,
23,
943
]
],
[
[
803,
63,
336
],
[
336,
24,
1065
],
[
1065,
24,
943
]
],
[
[
803,
24,
762
],
[
762,
24,
1065
],
[
1065,
24,
943
]
],
[
[
803,
63,
336
],
[
336,
25,
1456
],
[
1456,
24,
943
]
],
[
[
803,
63,
122
],
[
122,
25,
1135
],
[
1135,
23,
943
]
],
[
[
803,
24,
762
],
[
762,
25,
1456
],
[
1456,
24,
943
]
],
[
[
803,
21,
29162
],
[
29162,
60,
666
],
[
666,
24,
943
]
],
[
[
803,
63,
336
],
[
336,
24,
1619
],
[
1619,
63,
943
]
]
] | [
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
],
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
],
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Stupor"
],
[
"Stupor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Calcium acetate"
],
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
]
] | Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Bepridil and Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate and Calcium Phosphate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Bepridil and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate and Calcium Phosphate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Bepridil and Bepridil may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Calcium chloride (Compound) causes Stupor (Side Effect) and Stupor (Side Effect) is caused by Calcium acetate (Compound) and Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline |
DB00819 | DB06335 | 471 | 761 | [
"DDInter15",
"DDInter1646"
] | Acetazolamide | Saxagliptin | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
471,
24,
761
]
],
[
[
471,
6,
8374
],
[
8374,
45,
761
]
],
[
[
471,
21,
28722
],
[
28722,
60,
761
]
],
[
[
471,
63,
1573
],
[
1573,
24,
761
]
],
[
[
471,
24,
1042
],
[
1042,
24,
761
]
],
[
[
471,
24,
1019
],
[
1019,
63,
761
]
],
[
[
471,
1,
997
],
[
997,
24,
761
]
],
[
[
471,
6,
8374
],
[
8374,
45,
307
],
[
307,
23,
761
]
],
[
[
471,
21,
28722
],
[
28722,
60,
11525
],
[
11525,
1,
761
]
],
[
[
471,
21,
28784
],
[
28784,
60,
1577
],
[
1577,
24,
761
]
]
] | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Methazolamide"
],
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vildagliptin"
],
[
"Vildagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
]
] | Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Acetazolamide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Acetazolamide (Compound) resembles Methazolamide (Compound) and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Acetazolamide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Vildagliptin (Compound) and Vildagliptin (Compound) resembles Saxagliptin (Compound)
Acetazolamide (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin |
DB00424 | DB01403 | 19 | 9 | [
"DDInter896",
"DDInter1175"
] | Hyoscyamine | Methotrimeprazine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
19,
24,
9
]
],
[
[
19,
24,
1178
],
[
1178,
40,
9
]
],
[
[
19,
24,
1164
],
[
1164,
1,
9
]
],
[
[
19,
24,
401
],
[
401,
24,
9
]
],
[
[
19,
63,
508
],
[
508,
40,
9
]
],
[
[
19,
6,
2720
],
[
2720,
45,
9
]
],
[
[
19,
21,
28786
],
[
28786,
60,
9
]
],
[
[
19,
40,
1133
],
[
1133,
24,
9
]
],
[
[
19,
24,
407
],
[
407,
63,
9
]
],
[
[
19,
63,
352
],
[
352,
24,
9
]
]
] | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Urinary retention"
],
[
"Urinary retention",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) resembles {v} (Compound)",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
]
] | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Methotrimeprazine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methotrimeprazine (Compound)
Hyoscyamine (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Methotrimeprazine (Compound)
Hyoscyamine (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Methotrimeprazine (Compound)
Hyoscyamine (Compound) resembles Granisetron (Compound) and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine |
DB01168 | DB01365 | 1,053 | 280 | [
"DDInter1526",
"DDInter1151"
] | Procarbazine | Mephentermine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248) | Major | 2 | [
[
[
1053,
25,
280
]
],
[
[
1053,
64,
551
],
[
551,
1,
280
]
],
[
[
1053,
64,
80
],
[
80,
40,
280
]
],
[
[
1053,
25,
93
],
[
93,
1,
280
]
],
[
[
1053,
25,
22
],
[
22,
40,
280
]
],
[
[
1053,
18,
4930
],
[
4930,
57,
280
]
],
[
[
1053,
64,
1466
],
[
1466,
24,
280
]
],
[
[
1053,
24,
659
],
[
659,
63,
280
]
],
[
[
1053,
63,
455
],
[
455,
24,
280
]
],
[
[
1053,
64,
290
],
[
290,
25,
280
]
]
] | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} (Compound) resembles {v} (Compound)",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextroamphetamine"
],
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} (Compound) resembles {v} (Compound)",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mephentermine"
]
]
] | Procarbazine may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Mephentermine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Amphetamine and Amphetamine (Compound) resembles Mephentermine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Dextroamphetamine and Dextroamphetamine (Compound) resembles Mephentermine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine (Compound) resembles Mephentermine (Compound)
Procarbazine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Mephentermine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine
Procarbazine may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Mephentermine |
DB00373 | DB01285 | 461 | 708 | [
"DDInter1809",
"DDInter445"
] | Timolol | Corticotropin | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
461,
24,
708
]
],
[
[
461,
25,
455
],
[
455,
23,
708
]
],
[
[
461,
25,
659
],
[
659,
62,
708
]
],
[
[
461,
24,
1148
],
[
1148,
23,
708
]
],
[
[
461,
63,
245
],
[
245,
24,
708
]
],
[
[
461,
23,
126
],
[
126,
24,
708
]
],
[
[
461,
24,
1411
],
[
1411,
24,
708
]
],
[
[
461,
24,
1450
],
[
1450,
63,
708
]
],
[
[
461,
1,
729
],
[
729,
63,
708
]
],
[
[
461,
23,
286
],
[
286,
63,
708
]
]
] | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Timolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
]
] | Timolol may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Timolol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Timolol may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Timolol (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Timolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin |
DB00526 | DB01227 | 1,555 | 1,301 | [
"DDInter1355",
"DDInter1043"
] | Oxaliplatin | Levacetylmethadol | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862] | Major | 2 | [
[
[
1555,
25,
1301
]
],
[
[
1555,
64,
494
],
[
494,
1,
1301
]
],
[
[
1555,
24,
675
],
[
675,
1,
1301
]
],
[
[
1555,
24,
112
],
[
112,
23,
1301
]
],
[
[
1555,
63,
1648
],
[
1648,
24,
1301
]
],
[
[
1555,
24,
629
],
[
629,
24,
1301
]
],
[
[
1555,
24,
144
],
[
144,
63,
1301
]
],
[
[
1555,
25,
976
],
[
976,
63,
1301
]
],
[
[
1555,
25,
770
],
[
770,
24,
1301
]
],
[
[
1555,
24,
267
],
[
267,
25,
1301
]
]
] | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
]
] | Oxaliplatin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Levacetylmethadol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol
Oxaliplatin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol
Oxaliplatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may lead to a major life threatening interaction when taken with Levacetylmethadol |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.